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Abstract
High-risk neuroblastoma presents a significant therapeutic challenge because the 5-year survival rate
remains less than 30% despite the use of surgery, multi-agent chemotherapy, radiation, and autologous
bone marrow transplant. Novel therapeutic modalities are under development. The camptothecin analogs
topotecan and irinotecan have been identified as successful cytotoxic agents. For topotecan,
pharmacokinetically guided dosing to achieve a systemic exposure associated with preclinical anti-tumor
activity in neuroblastoma xenograft models is feasible and has elicited favorable responses in children
with high-risk neuroblastoma. However, some children with high-risk disease did not respond to the
putatively effective topotecan systemic exposure. These children represent a subset of the disease
intrinsically resistant to topotecan. Furthermore, mRNA expression of the adenosine triphosphate (ATP)binding cassette (ABC) transporters P-glycoprotein (Pgp) and multidrug resistance associated protein 1
(MRP1), which efflux many drugs used in neuroblastoma therapy, has been implicated in poor outcome in
neuroblastoma. Therefore, the purpose of our studies was to determine the role of ABC transport protein
expression in neuroblastoma resistance to the camptothecin analogs topotecan and irinotecan.
Initially studies focused on determining the expression of ABC transporters for which the camptothecin
analogs are substrates in neuroblastoma cell lines. By western blot analysis we demonstrated MRP4 and
Pgp expression in neuroblastoma cell lines relatively resistant to topotecan (e.g., NB1691), but not in cell
lines sensitive to topotecan (e.g., NB1643). In contrast, MRP1, MRP2, and breast cancer resistance
protein (BCRP) expression did not discriminate between sensitive and resistant cell lines. To determine
the functional contribution of both MRP4 and Pgp in neuroblastoma, we used RNA interference (RNAi) to
silence MRP4 and Pgp expression in NB1691. Long term, stable expression of retroviral vector mediated
short hairpin RNA (shRNA) reduced MRP4 and Pgp expression. Isogenic cell lines with reduced
expression of MRP4 and Pgp exhibited an increase in sensitivity to both topotecan and SN-38, the active
moiety of the prodrug irinotecan. In addition, we overexpressed MRP4 in NB1643, which resulted in
increased topotecan resistance.
The NB1691 cell lines with reduced MRP4 expression were subsequently transplanted as xenografts into
severe combined immunodeficiency (SCID) mice to determine the effect of MRP4 expression on the in
vivo response to topotecan. Unexpectedly, MRP4 silencing did not persist in vivo, and none of the
xenograft models responded to topotecan. However, MRP4 expression was associated with failure to
respond to topotecan, supporting the hypothesis that MRP4 mediates resistance to topotecan.
Finally, we determined the ABC transporter expression profile in primary tumor specimens from patients
with high-risk neuroblastoma who were treated with pharmacokinetically guided topotecan. Of the 14
specimens studied, MRP4 was expressed in 2 samples, and Pgp was expressed in 4 samples. BCRP was
not expressed in any of the neuroblastoma cell lines in vitro, but immunohistochemical analysis
demonstrated BCRP expression in nine primary neuroblastoma samples. Although we predicted that
MRP4 and/or Pgp expression would be associated with failure to respond to topotecan, results of
immunohistochemical analysis did not demonstrate such an association.
The results of the in vitro studies demonstrate that MRP4 and Pgp confer resistance to topotecan and
SN-38. In the xenograft studies, MRP4 expression was associated with failure to respond to topotecan.
However, this phenotype was not recapitulated in children treated with topotecan. These results may be
confounded by small sample size and timing of sample acquisition. Further investigation of the role of
ABC transporters in children with neuroblastoma who receive either topotecan or irinotecan may be
warranted. In addition to the camptothecin analogs, patients will receive other drugs effluxed by the ABC

transporters (e.g., doxorubicin, vincristine, etoposide, cyclophosphamide). Therefore, analyzing ABC
transporter expression by immunohistochemistry in diagnostic tumor specimens may help to select
agents not subject to efflux by ABC transporters expressed in the tumor. However, eliminating drugs
effluxed by ABC transporters from the treatment regimen creates a potential gap in therapy and may
reduce drug intensity. Therefore, further rational design and development of drugs that evade ABC
transporter-mediated efflux, and potentially other resistance mechanisms in neuroblastoma, is also
warranted.
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Abstract

High-risk neuroblastoma presents a significant therapeutic challenge because the
5-year survival rate remains less than 30% despite the use of surgery, multi-agent
chemotherapy, radiation, and autologous bone marrow transplant. Novel therapeutic
modalities are under development. The camptothecin analogs topotecan and irinotecan
have been identified as successful cytotoxic agents. For topotecan, pharmacokinetically
guided dosing to achieve a systemic exposure associated with preclinical anti-tumor
activity in neuroblastoma xenograft models is feasible and has elicited favorable
responses in children with high-risk neuroblastoma. However, some children with highrisk disease did not respond to the putatively effective topotecan systemic exposure.
These children represent a subset of the disease intrinsically resistant to topotecan.
Furthermore, mRNA expression of the adenosine triphosphate (ATP)-binding cassette
(ABC) transporters P-glycoprotein (Pgp) and multidrug resistance associated protein 1
(MRP1), which efflux many drugs used in neuroblastoma therapy, has been implicated in
poor outcome in neuroblastoma. Therefore, the purpose of our studies was to determine
the role of ABC transport protein expression in neuroblastoma resistance to the
camptothecin analogs topotecan and irinotecan.
Initially studies focused on determining the expression of ABC transporters for
which the camptothecin analogs are substrates in neuroblastoma cell lines. By western
blot analysis we demonstrated MRP4 and Pgp expression in neuroblastoma cell lines
relatively resistant to topotecan (e.g., NB1691), but not in cell lines sensitive to topotecan
(e.g., NB1643). In contrast, MRP1, MRP2, and breast cancer resistance protein (BCRP)
expression did not discriminate between sensitive and resistant cell lines. To determine
iv

the functional contribution of both MRP4 and Pgp in neuroblastoma, we used RNA
interference (RNAi) to silence MRP4 and Pgp expression in NB1691. Long term, stable
expression of retroviral vector mediated short hairpin RNA (shRNA) reduced MRP4 and
Pgp expression. Isogenic cell lines with reduced expression of MRP4 and Pgp exhibited
an increase in sensitivity to both topotecan and SN-38, the active moiety of the prodrug
irinotecan. In addition, we overexpressed MRP4 in NB1643, which resulted in increased
topotecan resistance.
The NB1691 cell lines with reduced MRP4 expression were subsequently
transplanted as xenografts into severe combined immunodeficiency (SCID) mice to
determine the effect of MRP4 expression on the in vivo response to topotecan.
Unexpectedly, MRP4 silencing did not persist in vivo, and none of the xenograft models
responded to topotecan. However, MRP4 expression was associated with failure to
respond to topotecan, supporting the hypothesis that MRP4 mediates resistance to
topotecan.
Finally, we determined the ABC transporter expression profile in primary tumor
specimens from patients with high-risk neuroblastoma who were treated with
pharmacokinetically guided topotecan. Of the 14 specimens studied, MRP4 was
expressed in 2 samples, and Pgp was expressed in 4 samples. BCRP was not expressed in
any of the neuroblastoma cell lines in vitro, but immunohistochemical analysis
demonstrated BCRP expression in nine primary neuroblastoma samples. Although we
predicted that MRP4 and/or Pgp expression would be associated with failure to respond
to topotecan, results of immunohistochemical analysis did not demonstrate such an
association.

v

The results of the in vitro studies demonstrate that MRP4 and Pgp confer
resistance to topotecan and SN-38. In the xenograft studies, MRP4 expression was
associated with failure to respond to topotecan. However, this phenotype was not
recapitulated in children treated with topotecan. These results may be confounded by
small sample size and timing of sample acquisition. Further investigation of the role of
ABC transporters in children with neuroblastoma who receive either topotecan or
irinotecan may be warranted. In addition to the camptothecin analogs, patients will
receive other drugs effluxed by the ABC transporters (e.g., doxorubicin, vincristine,
etoposide, and cyclophosphamide). Therefore, analyzing ABC transporter expression by
immunohistochemistry in diagnostic tumor specimens may help to select agents not
subject to efflux by ABC transporters expressed in the tumor. However, eliminating
drugs effluxed by ABC transporters from the treatment regimen creates a potential gap in
therapy and may reduce drug intensity. Therefore, further rational design and
development of drugs that evade ABC transporter-mediated efflux, and potentially other
resistance mechanisms in neuroblastoma, is also warranted.
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Chapter 1.

Introduction

Neuroblastoma is the most common extracranial solid tumor of childhood,
accounting for 7-10% of all childhood malignancies (1,2). Most patients present with
metastatic disease and have a poor prognosis (2,3). Therefore, improving therapy for
children with neuroblastoma is a major focus of ongoing preclinical and clinical research.
Results of work in one such area, overcoming multi-drug resistance, suggest that it may
be one of the many barriers to improving survival in children with this disease. The
molecular basis of multi-drug resistance in neuroblastoma is likely to be multifactorial,
caused by alterations in DNA repair pathways (4), increased intracellular detoxification/
inactivation of drugs (5,6), alterations in cell survival pathways (7,8), decreased binding
of drugs to the intended target (9), or increased efflux of chemotherapeutic agents from
cells.
Available data suggest that in neuroblastoma cells increased efflux may be a
determinant of resistance to chemotherapy. In solid tumor cells, drug efflux can be
mediated by members of the ABC transport protein superfamily. P-glycoprotein (Pgp)
and multi-drug resistance associated protein 1 (MRP1), both members of the ABC
transporter superfamily, are expressed in tumor specimens from children with
neuroblastoma (10,11,12). High Pgp and/ or MRP1 expression in neuroblastoma is
associated with poor prognosis. Also associated with poor prognosis is MYCN, a
transcription factor often amplified in neuroblastoma (13). The observation that MYCN
regulates the expression of several ABC transporters suggests two independent
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prognostic indicators for poor outcome: MYCN amplification and ABC transporter
expression (14).
Several drugs used in neuroblastoma therapy, including doxorubicin, vincristine,
and etoposide (15,16), are ABC transporter substrates.

The camptothecin analogs

topotecan and irinotecan are emerging as useful components of neuroblastoma therapy
(15,17) and are also substrates for ABC transporters (18). Therefore, the major focus of
this dissertation will be to assess the role of ABC transporter expression in resistance to
the cytotoxicity of topotecan and irinotecan in vitro, in vivo, and in children with
neuroblastoma. Expression of ABC transporters for which these camptothecin analogs
are substrates will be characterized in neuroblastoma cell lines demonstrating a spectrum
of sensitivity to these compounds. Molecular techniques including exogenous
overexpression and RNA interference (RNAi) will be used to evaluate the functional
contribution of individual transporters to drug resistance in vitro by quantitating
camptothecin analog sensitivity in isogenic cell lines. In addition, xenografts in mice will
be generated using these isogenic cell lines to assess the response to camptothecin
analogs. Lastly, primary tumor specimens from patients with high-risk neuroblastoma
will be analyzed to identify potential associations between clinical response to topotecan
and ABC transporter expression.

1.1

1.1.1

Neuroblastoma

Epidemiology
Neuroblastoma is the most common cancer in children younger than one year

(19). Furthermore, neuroblastoma is the most common extracranial solid tumor of
2

childhood. Neuroblastoma can arise from any tissue of sympathetic origin, but the
adrenal gland is the most common primary site. In the United States the annual
neuroblastoma incidence among children less than 15 years of age is 9.7 cases per million
(20). Neuroblastoma occurs at similar rates in both males and females, but a slightly
higher predominance is reported in whites than in blacks (10.2 versus 7.8 cases per
million, respectively). Most commonly neuroblastoma occurs in children younger than
two years. The median age at diagnosis is 22 months (21). Between 1985 and 1988 the
overall 5-year survival for children with neuroblastoma was 58% (1). However, only 34%
of children diagnosed with stage 4 neuroblastoma are long-term survivors (22). The
biological mechanisms that contribute to the poor survival in children with advanced
stage neuroblastoma are a subject of intense research. ABC transporter mediated efflux of
chemotherapeutic agents from tumor cells is among the many potential causes of poor
survival in children with neuroblastoma. Therefore, the major focus of this dissertation
will be on the role of ABC transporters in high-risk neuroblastoma, in particular, the role
of these proteins as determinants of sensitivity or resistance to the camptothecin analogs
topotecan and irinotecan.

1.1.2

Diagnosis
Patients with neuroblastoma can present with abdominal discomfort, fullness, or

pain (23). Hypertension, sweating, flushing, and tachycardia may also be present,
depending on tumoral catecholamine secretion. Before 1988 no uniform criteria for
neuroblastoma diagnosis, staging, and response evaluation existed, making it difficult to
compare clinical studies of neuroblastoma(24). From 1988-1993 the major pediatric
oncology groups from the United States, Europe, and Japan proposed consensus criteria
3

for neuroblastoma diagnosis, staging, and response evaluation (25). Tumor stage and
other prognostic indicators (e.g., MYCN status, DNA ploidy, Shimada Histology) are
assessed in order to stratify patients into risk groups which determine the course of
therapy.

1.1.3

Prognostic indicators and risk adapted therapy

1.1.3.1 Neuroblastoma disease stage as a prognostic indicator
Therapeutic modalities and treatment intensity are determined based upon a
child’s risk for a poor outcome (i.e., low, intermediate, and high-risk disease). Our study
focuses on high-risk neuroblastoma. Factors used to stratify neuroblastoma patients into
low, intermediate, or high-risk neuroblastoma (Table 1.1) include disease stage according
to the international staging system for neuroblastoma (INSS), a patient’s age, MYCN gene
copy number, Shimada histology, and DNA index (2). The patient’s age at diagnosis and
INSS stage are the two most important prognostic variables in childhood neuroblastoma.
The current standardized INSS defines six possible stages (Table 1.2) of childhood
neuroblastoma based upon tumor confinement, resection, metastasis to lymph nodes,
bone marrow, liver, or other sites (2). Children with advanced neuroblastoma (i.e., stage
3 or 4) have a poor prognosis.
1.1.3.2 Age at neuroblastoma diagnosis as a prognostic indicator
The correlation between young age at diagnosis (i.e., younger than 12-18 months)
and good prognosis is well documented (26). Recent evidence suggests that children
younger than 18 months have a more favorable prognosis than older children diagnosed

4

Table 1.1
INSS
Stage
1
2A/2B

3

4
4S

Neuroblastoma risk group stratification.
Age
(Years)
0-21
<1
≥1-21
≥1-21
≥1-21
<1
<1
≥1-21
≥1-21
≥1-21
<1
<1
≥1-21
<1
<1
<1
<1

MYCN Status
Any
Any
Non-amplified
Amplified
Amplified
Non-amplified
Amplified
Non-amplified
Non-amplified
Amplified
Non-amplified
Amplified
Any
Non-amplified
Non-amplified
Non-amplified
Amplified

Shimada
Histology
Any
Any
Any
Favorable
Unfavorable
Any
Any
Favorable
Unfavorable
Any
Any
Any
Any
Favorable
Any
Unfavorable
Any

DNA Index

Risk Group

Any
Any
NA
NA
NA
Any
Any
NA
NA
NA
Any
Any
NA
>1
=1
Any
Any

Low
Low
Low
Low
High
Intermediate
High
Intermediate
High
High
Intermediate
High
High
Low
Intermediate
Intermediate
High

Source: Castleberry, RP. Neuroblastoma, Eur J Cancer, 33: 1430-1437, 1997.
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Table 1.2
Stage
Stage 1
Stage 2A
Stage 2B
Stage 3
Stage 4
Stage 4S

International staging system for neuroblastoma.
Description
Localized tumor confined to area of origin; complete gross resection, ±
microscopic residual disease; ipsilateral and contralateral lymph nodes
are tumor negative
Unilateral with incomplete gross resection; ipsilateral and contralateral
lymph nodes tumor negative
Unilateral with complete or incomplete gross resection; ipsilateral lymph
node tumor positive; contralateral lymph node tumor negative
Tumor infiltrates across midline ± regional lymph node involvement; or
unilateral tumor with contralateral node involvement; or midline tumor
with bilateral lymph node involvement
Tumor dissemination to distant lymph nodes, bone marrow, liver, or
other organ except as in 4S
Localized primary tumor as for Stage 1 or 2 with dissemination to liver,
skin, or bone marrow with <10% nucleated marrow cells being tumor
cells

Source: Castleberry, RP. Neuroblastoma, Eur J Cancer, 33: 1430-1437, 1997.
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with neuroblastoma. Specifically, the 5-year event-free survival for 12- to 18-month old
children was more than 70-92% compared to 31-38% for older children (27,28,29).
1.1.3.3 MYCN amplification as a prognostic indicator
The oncogene MYCN located on chromosome 2p23-24 was first identified in
neuroblastomas (30), but is also amplified and overexpressed in other tumors including
retinoblastoma (31) and small-cell lung cancer (32). MYCN amplification is associated
with advanced stage neuroblastoma and rapid disease progression. Although the precise
molecular reasons for the association between MYCN amplification and poor prognosis
have not been determined, some of the MYCN target genes are involved in cell growth
and cell cycle progression (33). Cells overexpressing MYCN have shortened cell cycle
times (34). MYCN overexpression is also associated with increased metastatic potential
via reduced attachment to extracellular matrix (35).
Normally MYCN is expressed in the developing nervous system. N-Myc, the
protein product of the MYCN gene, localizes to the nucleus. N-Myc recognizes E-box
motifs in the promoter region of target genes and activates transcription (33,36). N-Myc
target genes include several ABC transporters which efflux many of the drugs used in
neuroblastoma therapy (reviewed in section 1.3).
Norris and colleagues evaluated the relationship between several prognostic
indicators in neuroblastoma and outcome, including MYCN amplification, age, tumor
stage, and MRP1 expression (10). High MRP1 mRNA expression was the prognostic
indicator most closely associated with outcome. In particular, high MRP1 levels predicted
reduced event-free and overall survival in children with neuroblastoma. After adjusting
outcome for MYCN amplification in multivariate analysis, MRP1 expression remained an
7

independent predictor of survival. Due to the prominence of MYCN amplification in
neuroblastoma and the molecular relationship between N-Myc and ABC transporter
expression, the association between MYCN amplification and poor prognosis may be due
to reduced intracellular accumulation of drugs.
1.1.3.4 Shimada Histology as a prognostic indicator
The histopathologic features of neuroblastoma can also be used as prognostic
indicators. Neuroblastoma histopathology consists of diffuse neuroblastic cell clusters
with irregular fibrovascular separations. The Shimada histology classification system was
proposed upon retrospective evaluation of untreated primary neuroblastoma specimens
from 295 patients for whom at least 2 years of follow-up data were available (37). This
system includes evaluation of stromal development and neuroblastic cell maturation/
differentiation. Initially specimens are classified as stroma-rich or stroma-poor. Stromarich tumors are divided into 3 subgroups: well-differentiated, intermixed, and nodular.
Both well-differentiated and intermixed tumors are classified as favorable (37,38,39).
Lastly, a nodular appearance confers unfavorable histology. Favorable or unfavorable
histology in stroma-poor cases depends on neuroblast differentiation, mitosiskaryorrhexis index (MKI), and age at diagnosis.
1.1.3.5 DNA Index
DNA Index is another feature of neuroblastoma used in risk group stratification to
guide therapy for children with neuroblastoma. DNA Index (also called DNA ploidy) is a
measure of tumor DNA content, which is measured by FACS analysis of propidium
iodide stained nuclei. Aneuploidy is considered a favorable clinical prognostic factor in
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neuroblastoma. Patients with diploid or tetraploid tumors have a poor prognosis in
comparison to those with triploid tumors (40,41,42,43).
1.1.3.6 Risk group stratification
Heterogeneity is a hallmark of neuroblastoma as demonstrated by variations in
age at diagnosis, DNA index, tumor histopathology, MYCN amplification, and other
biological features in neuroblastoma. Based on the heterogeneous survival rates for
children diagnosed with neuroblastoma, the Pediatric Oncology Group (POG) and
Children’s Cancer Group designed a risk stratification system to guide risk-related
therapy based upon prognosis (2). Stratification is based on five prognostic factors: INSS
stage, age at diagnosis, MYCN status, Shimada histology, and DNA index (Table 1.1).
This system stratifies children diagnosed with neuroblastoma into three risk groups: low,
intermediate, and high-risk disease.

1.1.4

Risk-adapted therapy

1.1.4.1 Low risk patients
Patients with low risk disease have greater than 95% predicted event-free survival
(2,44). Low risk neuroblastoma includes all patients with Stage 1 (localized) disease.
Localized disease is present in approximately 40% of neuroblastoma cases. In addition,
all children with Stage 2 disease are classified as low risk except those older than 1 yr
with MYCN amplification and unfavorable histology. In a POG study of 101 children
with localized low risk disease treated with surgery as the sole treatment modality, only 9
patients relapsed (44). Therefore, children with low risk localized disease should undergo
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surgical resection of the tumor. However, if local recurrence of the tumor is observed,
these patients can be treated with further surgery or chemotherapy.
1.1.4.2 Intermediate risk patients
Patients with intermediate risk disease have a 3-year predicted event-free survival
greater than 85% (2). Children with intermediate risk disease are stratified according to
Table 1.1. Therapy for intermediate risk disease includes surgery and chemotherapy.
Despite the favorable outcome for most patients with intermediate risk neuroblastoma,
advancements must be made in therapy to reduce acute and long-term toxicities.
1.1.4.3 High-risk patients
The focus of this dissertation will remain on the contribution of ABC transporters
to camptothecin analog resistance in high-risk neuroblastoma. Children diagnosed with
high-risk neuroblastoma have less than 30% predicted event-free survival. Children with
high-risk disease are stratified according to Table 1.1. Currently children diagnosed with
high-risk neuroblastoma receive multiple modalities of therapy including cytotoxic
chemotherapy, surgery, radiation, and bone marrow transplant.
The current protocol approach to high-risk neuroblastoma therapy includes
induction, continuation, and maintenance phases. The goal of induction is to reduce the
tumor mass by combining agents such as cisplatin, doxorubicin, etoposide, vincristine,
and cyclophosphamide (45). These five drugs are combined to take advantage of different
mechanisms of action and non-overlapping toxicities. Moreover, in accordance with the
Goldie-Coldman hypothesis, the risk of developing drug resistance is decreased by the
use of non-cross-resistant chemotherapeutic agents to achieve rapid cytoreduction (46).
In the second phase patients may receive continuation therapy that includes the same
10

agents used during induction. Alternatively, a myeloablative preparative regimen (e.g.,
melphalan, etoposide, and carboplatin or melphalan and total body irradiation) followed
by autologous stem cell transplantation (47,48) can be used to eradicate residual disease.
Due to the high relapse rate in children with high-risk neuroblastoma, the goal of
maintenance therapy is to eliminate minimal residual disease. Currently the
differentiation inducing agent 13-cis-retinoic acid (isotretinoin) is used in maintenance
therapy for high-risk neuroblastoma (48).
Due to the extremely poor outcome in children diagnosed with high-risk
neuroblastoma, several approaches to improving therapy have been investigated recently
or are currently in development. New therapeutic modalities such as
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I-MIBG

(norepinephrine analog that concentrates in sympathetic tissue) or anti-GD2 (antigen
highly expressed in neuroectodermal tumors) antibodies are under investigation. For
drugs with wide variability in pharmacokinetics such as topotecan, approaches to
minimize interindividual variability or to achieve the putatively effective systemic
exposure have been evaluated. For example, the pharmacokinetically guided approach to
topotecan dosing in children with high-risk neuroblastoma showed an excellent response
to single agent topotecan targeted to the putatively effective systemic exposure (49,15).
However, chemotherapeutic agents are rarely used as single agents. Due to the favorable
outcome in some children with neuroblastoma, pharmacokinetically guided topotecan has
also been evaluated in combination with other drugs active in neuroblastoma such as
cyclophosphamide.
Despite the extremely favorable response to topotecan in children with high-risk
neuroblastoma (60% response rate), the lack of a response in 40% of the children treated

11

with pharmacokinetically guided topotecan indicates clinical resistance to topotecan in
neuroblastoma (15). The mechanisms for this resistance are not completely understood.
Identifying the molecular determinants of resistance in children with either intrinsic
resistance at therapy initiation or acquired resistance after several cycles of chemotherapy
may help to guide selection of the most active treatment regimens for individual patients.
Resistance in neuroblastoma is likely to be a multifactorial phenomenon. For the
camptothecin analogs, mutations in drug target (i.e., topoisomerase I) can lead to
resistance (50,51). In addition, resistance can be caused by increased intracellular
detoxification and alterations in cell death or survival pathways. Finally, ABC
transporters that efflux camptothecin analogs can confer resistance.
The studies of ABC transporters in neuroblastoma have generated controversial
and conflicting results. High levels of MRP1 mRNA expression in primary, untreated
neuroblastoma are associated with reduced survival and event-free survival in patients
with neuroblastoma (10). Moreover, in tumors without MYCN amplification, high levels
of MDR1 mRNA expression are associated with poor cumulative survival and event-free
survival (11). However, the prognostic significance of P-glycoprotein expression, which
is encoded by MDR1, in neuroblastoma remains controversial (52). For example, de
Cremoux and colleagues have demonstrated that high levels of MRP1 or MDR1 did not
predict neuroblastoma response in a study of biopsy samples from 29 high-risk patients
(53). In contrast Norris and colleagues have demonstrated that MRP1 is a significant,
independent predictor of poor prognosis in a prospective analysis of a large group of
children with neuroblastoma (10). Despite the controversial results of studies of the
relation between ABC transporter expression in neuroblastoma and clinical outcome, the
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drugs that are subject to ABC transporter-mediated resistance are used in the treatment of
neuroblastoma. For example, the camptothecin analogs topotecan and irinotecan have
anti-tumor activity in children with neuroblastoma, but these drugs are substrates for
several of the ABC transporters. Elucidation of the role of ABC transporters in resistance
of primary tumors to topotecan and irinotecan may improve our ability to obtain the
maximum therapeutic benefit of topotecan and irinotecan in treating neuroblastoma

1.2

Camptothecin analogs are topoisomerase I interactive agents
Camptothecin is a naturally occurring alkaloid isolated from the Camptotheca

acuminata tree (54). Despite demonstrated anti-tumor activity, the clinical utility of
camptothecin sodium is limited due to severe toxicity, including hemorrhagic cystitis
characterized by necrotic ulcerations throughout the urinary tract (55,56,57). Other
toxicities associated with camptothecin sodium include nausea, vomiting, alopecia,
stomatitis, and diarrhea. The dose limiting toxicity (DLT) of camptothecin sodium is
myelosuppression, including neutropenia and thrombocytopenia. However, due to the
promising anti-tumor properties of camptothecin sodium and the pH dependent toxicity
in the urinary bladder, more water-soluble camptothecin analogs topotecan and irinotecan
were synthesized. Results of early clinical trials with these compounds demonstrated a
more acceptable toxicity profile and retention of the promising anti-tumor activity of the
parent compound. Figure 1.1 shows chemical structures of the parent pentacyclic
camptothecin as well as topotecan, irinotecan, and SN-38 (the active metabolite of the
prodrug irinotecan). The clinical utility of both topotecan and irinotecan has been
demonstrated in pre-clinical and clinical studies of several pediatric tumor models,
including neuroblastoma.
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Camptothecin analogs undergo reversible pH-dependent conversion between the openring carboxylate form and closed-ring lactone form. At physiologic pH (7.4) the
carboxylate form of the camptothecin analog predominates; whereas, the lactone form
predominates under acidic conditions. The camptothecin analog lactone form is
responsible for the pharmacological activity at the site of action by interacting with the
target enzyme topoisomerase I.
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Topoisomerase I is the molecular target of camptothecin analogs. Topoisomerase
I relieves torsional strain in DNA by cleaving of a single DNA strand, permitting the
second DNA strand to pass through the break, and then religating the cleaved strand.
Camptothecin analogs stabilize these transient DNA-topoisomerase I complexes during
DNA synthesis. The replication fork arrests upon collision with the resultant covalent
DNA-topoisomerase I complexes, which are thought to generate lethal DNA strand
breaks (58).
At physiological pH the α-hydroxylactone E-ring ring system undergoes
reversible hydrolysis to form the anionic carboxylic acid moiety (58). In vitro studies of
camptothecin analogs have demonstrated that the pharmacologically active form is the
closed ring lactone form (59). The open E-ring carboxylate conformation has little if any
cytotoxic effect (60). Because the lactone form of camptothecin analogs is considered the
active conformer, phase I and II trials in children have extensively investigated the
pharmacokinetics of topotecan lactone and irinotecan/SN-38 lactone.

1.2.1

Topotecan
Topotecan (9-dimethylaminomethyl-10hydroxycamptothecin, Hycamtin®) is

FDA-approved for treatment of ovarian cancer and small cell lung cancer in adults.
Preclinical xenograft studies in mice have demonstrated activity of protracted topotecan
administration for treatment of several pediatric solid tumors including neuroblastoma,
medulloblastoma, glioblastoma, and rhabdomyosarcoma (61,62). Importantly, a steep
topotecan lactone systemic exposure- response relationship has been documented.
Zamboni and colleagues investigated the relationship between topotecan systemic
exposure and response in a panel of six neuroblastoma xenograft models (61). Mice
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bearing subcutaneous neuroblastoma xenografts were treated with a range of topotecan
dosages (0.36 to 2 mg/kg) daily for 5 days for 2 weeks [(dx5)2] every 21 days for 3
courses. The investigators determined the topotecan lactone systemic exposure associated
with response in a panel of six neuroblastoma xenografts (i.e., NB1382.2, NB1643,
NB1691, NB1771, NBEB, and NBSD). Four of the 6 neuroblastoma xenograft models
demonstrated a complete response to topotecan dosages associated with a topotecan
lactone area under the concentration-time curve (AUC) less than or equal to 88
ng/mL*hr. Both in vivo and in vitro NB1643 was relatively sensitive to topotecan;
whereas, NB1691 required a topotecan lactone systemic exposure of 290 ng/mL*hr to
achieve a complete response (63). Despite the resistance of NB1691 to topotecan both in
vitro and in vivo, the favorable response of four other neuroblastoma xenograft models to
topotecan provided a strong basis for further study of topotecan in neuroblastoma clinical
trials.
Several topotecan dosage schedules have been evaluated in phase I and II clinical
trials in children. A 72 hr continuous topotecan infusion showed minimal anti-tumor
activity in neuroblastoma (Table 1.3). A five-day schedule of topotecan was minimally
active in neuroblastoma, but interindividual variability in topotecan pharmacokinetics
was high (66, 67).
However, topotecan is an S-phase selective agent. Maximizing drug exposure to
cells (particularly those with long cell-cycle times and low growth fractions) in S-phase
can be achieved using protracted administration schedules such as daily for five days for
two to three weeks (68). Studies of topotecan in xenograft models demonstrated the
superiority of protracted schedules of administration over high doses administered
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Table 1.3
Topotecan clinical trials in children with recurrent or refractory solid
tumors including neuroblastoma.
Phase

Dosage

N
(n with
NB)
27 (9)

MTD
(mg/m2/d)

DLT

I

72 hr CI

II

Responses
in children
with NB
1 CR at 1.3
mg/m2/day
maintained
for 8
months; 5
SD
1 CR

1.0
with GCSF

Myelosuppression

72 hr CI

93 (not
reported)

1.3

Myelosuppression

I

Dx5
Q 21d
30 min
i.v.
infusion

40 (9)

1.4
without
G-CSF;
2.0
with GCSF

Neutropenia,
thrombocytopenia

3 PR

II

Dx5 Q
21d by
30 min
i.v.
infusion

20 (13)

1.48

Anemia,
neutropenia,
thrombocytopenia

2 PR; 4 SD

Notes

Ref.
(64)

Schedule
inactive
in
recurrent/
refractory
NB
7-fold
range in
topotecan
lactone
systemic
clearance

(65)

(66)

(67)

Abbreviations: NB- neuroblastoma, MTD- maximum tolerated dose, DLT- dose limiting
toxicity, CI- continuous infusion, G-CSF- granulocyte colony stimulating factor, CRcomplete response, Dx5 Q 21 d- daily for 5 days every 21 days, PR- partial response, SDstable disease
Sources: Pratt CB, et al. Phase I study of topotecan for pediatric patients with malignant
solid tumors, J Clin Oncol, 12: 539-543, 1994.
Blaney SM, et al. Phase II trial of topotecan administered as 72-hour continuous infusion
in children with refractory solid tumors: a collaborative Pediatric Branch, National
Cancer Institute, and Children's Cancer Group Study, Clin Cancer Res, 4: 357-360, 1998.
Tubergen DG, et al. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD)
study of topotecan using a five-day course in children with refractory solid tumors: A
Pediatric Oncology Group Study, J Ped Hem/Onc, 18: 352-361, 1996.
Langler A, et al. Topotecan in the treatment of refractory neuroblastoma and other
malignant tumors in childhood - a phase-II-study, Klin Padiatr, 214: 153-156, 2002.
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Intermittently (68). Based on the strength of these preclinical data, Santana and
colleagues evaluated the protracted administration with pharmacokinetically guided
dosing of topotecan to minimize variability in systemic exposure and achieve the
putatively effective topotecan systemic exposure in children.
Santana and colleagues conducted a pilot study of protracted topotecan in children
with refractory solid tumors (Table 1.4) (49). Due to the wide interpatient variability in
topotecan pharmacokinetics and the documented relationship between topotecan systemic
exposure and response, the investigators used a pharmacokinetically guided dosing
approach to minimize interpatient variation in topotecan systemic exposure. This
approach also removes interindividual variability as a factor contributing to resistance.
The single day topotecan lactone systemic exposure evaluated in children was based upon
anti-tumor response in xenograft models at topotecan lactone AUC ranging from 88 to
144 ng/mL*hr (68,66,61).
In the pilot Phase I trial the pharmacokinetically guided dosing resulted in
achieving the targeted systemic exposure in 78% (46 of 59) of the pharmacokinetic
studies (49). The investigators also demonstrated a significant reduction in AUC values
outside of the targeted range in comparison to that which would be achieved using a fixed
dosing approach based solely on body surface area. Due to the manageable toxicity and
favorable responses to pharmacokinetically guided dosing of protracted topotecan, a
prospective phase II trial was conducted in previously untreated high-risk neuroblastoma
(Table 1.4) (15). The pharmacokinetic targeting success rate was 72%, indicating the
superiority of this individualized approach to topotecan dosing over fixed dosing to
achieve a desired AUC.
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Table 1.4
Clinical trials of topotecan pharmacokinetically guided dosing in
children with solid tumors including neuroblastoma.
Phase

I

II

Dosage
Schedule

N (n
with
NB)

Population

(Dx5)2
15 (5)
Q 24-28 d
30 min
i.v. infusion
(Dx5)2
30 (30)
Q 28 d
30 min
i.v. infusion

Recurrent/
refractory
solid tumors
Previously
untreated
high-risk NB

Single Day
Topotecan
Lactone
Target
(ng/mL*hr)
Cohort 1:
120-160
Cohort 2:
80-120
80-120

NB
Reference
Responses

Cohort 1:
1 PR
Cohort 2:
1 PR
1 CR
17 PR

(49)

(15)

Abbreviations: NB- neuroblastoma, (Dx5)2- daily for 5 days for 2 weeks, Q 24-28 devery 24 to 28 days, i.v.- intravenous, Q 28 d, every 28 days, PR- partial response, CRcomplete response
Sources: Santana VM, et al. A pilot study of protracted topotecan dosing using a
pharmacokinetically guided dosing approach in children with solid tumors, Clin Cancer
Res, 9: 633-640, 2003.
Santana VM, et al. Improved response in high-risk neuroblastoma with protracted
topotecan administration using a pharmacokinetically guided dosing approach, J Clin
Oncol, 23: 4039-4047, 2005.
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The feasibility of pharmacokinetically guided topotecan dosing determined in the
pilot study was confirmed in this phase II study. The 60% response rate (complete and
partial responses) was excellent in these previously untreated patients, especially in
comparison to studies in relapse patients where the response rate was only 15% (67). The
60% response rate to pharmacokinetically guided topotecan was also more favorable than
the 40% response rate observed in a Phase II POG study of topotecan (2 mg/kg
administered dx5) in 33 children with previously untreated Stage IV neuroblastoma (3).
The higher response rate in the Santana study might be due to several factors including
number of days of topotecan, dosage of topotecan, and systemic exposure of topotecan.
The patients with refractory tumors on the Langler study (67) might represent a more
drug resistant disease subset than the previously untreated population in the Santana
study. In the Langler and POG (3) studies, patients received only 5 days of topotecan
rather than 10 days over 2 weeks. Moreover, the daily topotecan dosages were lower in
the Langler and (median 1.48, range 0.4-1.7 mg/m2) and POG studies (2 mg/m2) than in
the Santana study (median 2.7, range 0.95-3.8 mg/m2). However, since topotecan
pharmacokinetics were not reported in the Langler or POG studies, direct comparison of
topotecan pharmacokinetics cannot be made to those reported by Santana and colleagues.
Based on the documented interindividual variability in topotecan pharmacokinetics,
substantial variation in topotecan systemic exposure was likely present in the studies
using a fixed dosing approach. The approach to topotecan fixed dosing for 5 days every
21 days without dosage adjustment based on a targeted systemic exposure is probably
subtherapeutic, especially in comparison to the protracted topotecan schedule targeting a
systemic exposure of 80-120 ng/mL*hr. Based on the systemic exposure-response
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relationship, interindividual variability in drug exposure likely contributes to some cases
of apparent topotecan resistance. However, the pharmacokinetic guided topotecan dosing
approach minimizes interindividual variability in topotecan systemic exposure.
Although protracted topotecan with pharmacokinetically guided dosing
adjustments to achieve an AUC of 80-120 ng/mL*hr resulted in an excellent response
rate in chemotherapy naïve children diagnosed with neuroblastoma, the tumor response
rate (60%) was lower than the pharmacokinetic targeting success (72%). The patients
who did not respond to pharmacokinetically guided protracted topotecan represent a
subset of the disease that is clinically resistant to topotecan.
Resistance to topotecan can be multifactorial. Reduced expression of
topoisomerase I, the molecular target of topotecan, can result in topotecan resistance.
Topoisomerase I mutations that affect topotecan binding may confer topotecan resistance
(50,51). Increased DNA repair via tyrosyl-DNA-phosphodiesterase overexpression can
also lead to camptothecin analog resistance(69). Finally, ABC transporter-mediated
efflux from the cell may result in topotecan resistance.

1.2.2

Irinotecan
Irinotecan (7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin,

Camptosar®), a camptothecin analog, has been evaluated in a variety of pediatric tumors,
including neuroblastoma. The prodrug irinotecan has been FDA approved for treatment
of metastatic colorectal cancer. Irinotecan is metabolized by carboxylesterases to the
active metabolite SN-38. Preclinical and clinical studies have demonstrated that i.v.
irinotecan was also active against pediatric tumors including rhabdomyosarcoma,
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medulloblastoma, glioblastoma, and neuroblastoma (62,70). Oral irinotecan was active in
a panel of six neuroblastoma xenograft models (71).
Vassal and colleagues demonstrated irinotecan activity in a panel of three
neuroblastoma xenografts established from patients with poor prognosis (72). IGR-N835
was established from a previously treated patient with MYCN amplified stage IV disease
lacking MDR1 expression. IGR-NB3 and IGR-NB8 were derived from two patients with
untreated stage III disease, MYCN amplification, and MDR1 overexpression, each of
which was refractory to chemotherapy. A complete or partial response to irinotecan
(either using a dx5 or q4dx5 administration schedule) was achieved in all 3 xenograft
models studied. Although several investigators have demonstrated resistance to irinotecan
and SN-38 in Pgp overexpressing cell lines in vitro (73,74), the response to irinotecan of
xenografts overexpressing Pgp suggests that Pgp did not play a major role in irinotecan
resistance in this model. However, to confirm this hypothesis it would be necessary to
demonstrate irinotecan efficacy in patients with neuroblastoma that overexpresses Pgp.
In contrast to the dx5 irinotecan dosing approach reported by Vassal et al,
Thompson and colleagues demonstrated the anti-tumor activity of protracted (i.e., daily
for 5 days for 2 weeks) i.v. irinotecan in a panel of 6 neuroblastoma xenografts (70). The
characteristics of each xenograft model are listed in Table 1.5. A single course of
irinotecan 10 mg/kg daily for 5 days for 2 weeks induced a complete response in
NB1691, NB1643, NBEB, and NB1382.2 tumors. Also, a partial response was achieved
in NB1771. However, NBSD, which was derived from a bone marrow aspirate, did not
respond significantly to this irinotecan dosage. This might indicate that neuroblastoma
bone marrow metastases are more refractory to irinotecan than the primary tumor. The
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Table 1.5
Xenograft

Neuroblastoma xenograft features.
Stage

Site

NB1691

D

Adrenal

NB1643
NB1382.2

D
C

NB1771
NBSD

D
D

NBEB

D

Prior Therapy

AraC, Dauno, 6-TG, VP-16,
5-azacytidine
Retro-peritoneal None
Retro-peritoneal VCR, VP-16, CTX, CDDP,
carboplatin
Adrenal
None
Bone marrow CTX, Dox, CDDP, VM-26
aspirate
Adrenal
CTX, Dox,CDDP,VM-26

MYCN
Amplification
Yes
Yes
Yes
Yes
Yes
No

Abbreviations: AraC- cytosine arabinoside, Dauno- daunorubicin, 6-TG- 6-thioguanine,
VP-16- etoposide, VCR- vincristine, CTX- cyclophosphamide, CDDP- cisplatin, Doxdoxorubicin, VM-26- teniposide. (Note: stage D is equivalent to current INSS stage 4.)
Source: Thompson J, et al. Efficacy of systemic administration of irinotecan against
neuroblastoma xenografts, Clin Cancer Res, 3: 423-431, 1997.
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investigators also determined that the irinotecan and SN-38 systemic exposures
associated with the minimum effective dose in xenograft models can also be achieved
clinically in children with cancer (17). Furthermore, at systemic exposures tolerated in
children (75) oral irinotecan elicited anti-tumor responses in the same panel of
neuroblastoma xenografts (71).
Several schedules of irinotecan administration have been evaluated in children
with solid tumors in phase I trials (Table 1.6). The major toxicities associated with
irinotecan were myelosuppression and diarrhea. Favorable responses were observed in
several tumor types, for neuroblastoma in particular. Based solely on the phase I clinical
data, the optimal irinotecan schedule cannot be determined unequivocally. However, the
extensive preclinical studies of Houghton and colleagues have demonstrated the
superiority of protracted irinotecan to shorter schedules. Moreover, due to the potential
for failure to respond to irinotecan, future clinical trials of irinotecan should include
prospective evaluation of factors that might influence anti-tumor response, including
expression of ABC transporters in the tumor.

1.3

ABC transporters
The human ABC superfamily of transmembrane proteins contains 49 genes

divided into 7 subfamilies (ABCA through ABCG) based upon gene structure, order of
domains, and amino acid sequence homology (79). ABC transporters are expressed in
both normal and tumor tissues and efflux a variety of endogenous substrates and
xenobiotics from cells against a concentration gradient. ABC transporters expressed in
normal tissues protect cells from toxic substances. ABC transporters expressed in normal
tissues also play a role in the pharmacokinetics (absorption, distribution, metabolism, and
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Table 1.6
Irinotecan phase I clinical trials in children with recurrent or
refractory solid tumors including neuroblastoma.
Dosage
Schedule

N
(n with NB)

(Dx5)2 by 1
hr i.v.
infusion
Dx5 q 21 d
by 1 hr i.v.
infusion

23 (5)

20 mg/m2/day, diarrhea

35 (7)

QW for 3W
by 1 or 2 hr
i.v. infusion

Less heavily
pretreated:
48 (5)
More heavily
pretreated:
33 (11)
28 (26)

Heavily pretreated
stratum: 39 mg/m2/day,
neutropenia/
thrombocytopenia;
Less heavily pretreated
stratum: 50 mg/m2/day,
diarrhea
600 mg/m2/dose, delayed
diarrhea and cholinergic
syndrome for less
heavily pretreated;
neutropenia for heavily
pretreated
160-180 mg/m2/day,
myelosuppression
(hematopoietic lineages)
and diarrhea

Dx3 by 2 hr
i.v. infusion
q 28d

MTD, DLT

Responses in
children with
NB
1 PR

Reference
(17)

1 PR, 1 SD

(76)

1 PR
persisted for
5 courses

(77)

4 PR

(78)

Abbreviations: NB- neuroblastoma, MTD- maximum tolerated dose, DLT- dose limiting
toxicity, (Dx5)2- daily for 5 days for 2 weeks, Dx5 q 21 d- daily for 5 days every 21
days, QW- every week, 3W- 3 weeks, PR- partial response, SD- stable disease
Sources: Furman WL, et al. Direct translation of a protracted irinotecan schedule from a
xenograft model to a phase I trial in children, J Clin Oncol, 17: 1815-1824, 1999.
Blaney S, et al. A phase I study of irinotecan in pediatric patients: a pediatric oncology
group study, Clin Cancer Res, 7: 32-37, 2001.
Vassal G, et al. A phase I study of irinotecan as a 3-week schedule in children with
refractory or recurrent solid tumors, J Clin Oncol, 21: 3844-3852, 2003.
Mugishima H, et al. Phase I study of irinotecan in pediatric patients with malignant solid
tumors, J Pediatr Hematol Oncol, 24: 94-100, 2002.
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excretion) of drugs that are ABC transporter substrates. Finally, multi-drug resistance via
drug efflux is one of the functional consequences of ABC transporter expression in
malignant cells.
ATP binding or hydrolysis drives this efflux process. Several mechanisms for
extruding substrates from a cell have been proposed, including those of a classical pump,
a flippase, a hydrophobic vacuum cleaner, and an ATP switch. According to the classical
pump model, ABC transporters remove substrates directly from the cytoplasm to the
extracellular space. However, because substrates have been shown to enter the transporter
via the membrane and not the cytoplasm, ABC transporters likely function according to
an alternate mechanism (80). According to the flippase model, a transporter flips a
substrate from the inner membrane leaflet to the outer membrane leaflet from which the
substrate could diffuse into the extracellular environment (81). The hydrophobic vacuum
cleaner model proposes that the transmembrane domains associate to form a channel in
the plasma membrane (82). Upon passive diffusion of a substrate into the lipid bilayer,
the transporters detect substrates in the membrane and efflux them from the cell. The
ATP switch model is similar to the hydrophobic vacuum cleaner model. Upon substrate
binding to a high-affinity site on the transmembrane domain (TMD) of the inner
membrane leaflet, two ATP molecules bind the nucleotide binding domain (NBD),
inducing a conformational change in the TMD (83). This conformational change exposes
the substrate to the extracellular space, and the affinity of the transporter for the substrate
is reduced. Hence, the bound drug is released into the extracellular space. Following ATP
hydrolysis, inorganic phosphate and ADP are released, and the transporter is restored to
its basal conformation.
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In addition to similar mechanisms of action, ABC transporters share structural
features. Structural domains common to this protein superfamily include a TMD and a
highly conserved ATP-binding cassette, which is also called the nucleotide binding
domain (NBD). The ATP-binding domains known as Walker A and Walker B motifs in
the NBD are separated by 90-120 amino acids (79). A functional transporter is comprised
of at least 2 TMDs, each of which contains 6-11 membrane spanning α-helices.
The ABC transporters Pgp, MRP1, MRP2, MRP4, and BCRP may play a role in
resistance to topotecan, irinotecan, and SN-38. The role of these transporters in resistance
to topotecan, irinotecan, and SN-38 in addition to what is known about their expression in
neuroblastoma will be summarized below.

1.3.1

P-glycoprotein
P-glycoprotein (Pgp) was the first member of the ABC transporter superfamily

described(84), and it is encoded in humans by the gene ABCB1, also known as MDR1.
The protein product of the MDR1 gene is a 170 kDa plasma membrane glycoprotein. Pgp
has also been shown to be expressed in the membranes of organelles such as the nuclear
envelope and Golgi apparatus (85,86). Although the full-length MDR1 gene was not
cloned until 1986 (87), Pgp expression in multi-drug resistant cell lines was first
demonstrated in 1976 (84).
Immunohistochemical analysis has demonstrated Pgp expression in various
human tissues. Pgp was expressed in the epithelium of the gastrointestinal tract and
bronchus, and in vascular endothelium, notably in the blood-brain barrier. Pgp was also
expressed in secretory and excretory tissues including bile canaliculi and ductules, renal
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tubules, pancreatic ducts, mammary glands, prostate glands, salivary glands, and adrenal
glands (88).
1.3.1.1 Pgp substrates
Pgp substrates include a wide variety of structurally diverse, hydrophobic
xenobiotics including anthracyclines, anthracenes, vinca alkaloids, epipodophyllotoxins,
tubulin polymerizing drugs, HIV-1 protease inhibitors, and fluorophores. Pgp substrates
used in neuroblastoma therapy include doxorubicin, vincristine, etoposide, and teniposide
(18). In addition, the camptothecin analogs topotecan and irinotecan, which are
components of neuroblastoma therapy, have been evaluated as Pgp substrates with
conflicting results (73,89,90).
The first studies demonstrating that Pgp confers resistance to topotecan were
conducted in drug selected cell lines. Chinese hamster ovary cells selected for colchicine
resistance (CHRC5) that overexpressed Pgp were 15 times more resistant to topotecan
than the parental cell line (AuxB1) and 10 times more resistant to SN-38 (89,73).
Topotecan and SN-38 accumulation and drug-stabilized topoisomerase I- DNA
complexes were reduced in CHRC5 compared to AuxB1, suggesting reduced intracellular
topotecan or SN-38 in CHRC5 due to Pgp-mediated efflux. However, these were drug
selected cell lines, and expression of other transporters that might confer topotecan
resistance (e.g., BCRP or MRP1) cannot be ruled out. These studies were performed prior
to identification of other drug transporters; hence, the contribution of other ABC
transporter families to the results of these studies is unknown.
In contrast to the drug selected cell lines used by Hendricks (89) and Mattern et al
(73), Jansen and colleagues demonstrated irinotecan and SN-38 resistance in cells
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transfected with MDR1 cDNA (74). A melanoma cell line transfected with MDR1 was 5
times more resistant than the parental cell line to irinotecan and only 1.4 times as resistant
to SN-38. When these same cell lines were implanted as xenografts in mice, virtually no
difference was observed in sensitivity to irinotecan, indicating that the in vitro and in vivo
model systems were not equivalent. Specifically, the xenografts had higher
topoisomerase I activity than the cell lines in vitro, which may account for the lack of
resistance observed in vivo. Similar to the results of Mattern and colleagues, the in vitro
level of resistance to topotecan and SN-38 was one to two orders of magnitude lower
than for the classical Pgp substrates doxorubicin and vincristine.
Pommier and colleagues used two in vitro systems to demonstrate that Pgp
confers resistance to topotecan (90). First, KB-V1, a human carcinoma cell line selected
for vinblastine resistance, was more resistant to camptothecin, topotecan, and SN-38 than
the parental KB-3-1 cell line. In addition to the vinblastine selected cell line,
camptothecin analog cytotoxicity was studied in an isogenic system, NIH3T3 and NIHMDR-G185. The resistant cell line was transfected with a plasmid encoding Pgp and
maintained in colchicine. NIH-MDR-G185 showed increased resistance to topotecan, but
not camptothecin or SN-38. The investigators did, however, make the important
distinction that even though Pgp confers resistance to topotecan, Pgp confers a much
higher level of resistance to drugs such as doxorubicin.
1.3.1.2 Pgp expression in neuroblastoma
Multidrug resistance conferred by ABC transporters can be either intrinsic or
acquired. Intrinsic resistance of an untreated tumor can be due to expression of ABC
transporters. Acquired resistance refers to chemotherapeutic selection of drug resistant
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clones (e.g., those expressing ABC transporters). Intrinsic and acquired resistance has
been studied in neuroblastoma, and both may have implications for clinical outcomes
including response and survival.
Pgp is expressed in many tumor types, especially those that arise from tissues that
normally express Pgp. Using three monoclonal antibodies to different Pgp epitopes, Pgp
expression has been demonstrated prior to chemotherapy in non-Hodgkin’s lymphoma,
intestinal leiomyosarcoma, adenocarcinoma of the stomach, colon, kidney, breast, and
adrenal cortex (88). In addition, Fojo and colleagues demonstrated that MDR1 mRNA is
expressed in the adrenal gland, adrenal medulla, and in neuroblastoma tumor samples of
unspecified stage taken from 3 patients following relapse after treatment with vincristine
and doxorubicin (91). Although the investigators did not evaluate the relationship
between MDR1 expression and outcome, several other groups have conducted such
analyses in neuroblastoma.
Results of studies evaluating the significance of Pgp mRNA or protein expression
in neuroblastoma are inconsistent (92,93,52,10). The inconsistencies may be explained by
small study populations, differences in prior therapy, absence of paired samples at
diagnosis and relapse, failure to isolate tumor tissue from normal tissue, and the potential
lack of correlation between mRNA and protein expression level (94). The most reliable
studies using immunohistochemistry to detect protein expression in neuroblastoma
biopsies have demonstrated that overall survival is significantly lower in children with
tumors that express Pgp at diagnosis (93) and Pgp expression at diagnosis increases the
risk of death in neuroblastoma by 60% (52). Therefore Pgp expression in neuroblastoma
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is likely an unfavorable feature and may confer poor prognosis in neuroblastoma at least
perhaps in an as yet undefined subset of patients (93,52).

1.3.2

MRP1
The human MRP1 (ABCC1) gene contains 31 exons, maps to chromosome 16p13,

and encodes a 190 kDa protein. MRP1 was first identified in a lung cancer cell line
selected for doxorubicin resistance without expression of Pgp (95). MRP1 mRNA
expression was ubiquitous in a panel of human tissues (96,97). In addition, western blot
and immunohistochemical analysis of normal human tissues demonstrated essentially
ubiquitous MRP1 expression (98). MRP1 was expressed in the adrenal gland, lung, heart,
skeletal muscle, liver, spleen, kidney, stomach, small and large intestine, prostate gland,
testis, ovary, and erythrocytes. However, MRP1 was not observed in endothelium.
1.3.2.1 MRP1 substrates
Some overlap exists between Pgp and MRP1 substrates. As for Pgp, MRP1
transports both endogenous and xenobiotic substrates. MRP1 substrates include
glutathione S-conjugates, sulfate conjugates, and glucuronides (Table 1.7) (99). In an
isogenic system Chen and colleagues demonstrated an ATP-dependent reduction in
intracellular accumulation of both irinotecan and SN-38 in KB-3-1 cells transfected with
MRP1 cDNA (100). Furthermore, compared to the parental cell line the MRP1
overexpressing cell line was 7 and 15 times more resistant to irinotecan and SN-38,
respectively.
Allen and colleagues knocked out the murine orthologs of human MRP1 and
MDR1 (Mrp1, Mdr1a, and Mdr1b respectively) in murine embryonic fibroblasts (MEF)
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Table 1.7

Partial list of endogenous and xenobiotic MRP1 substrates.

Class
Drugs

GSH conjugates

Glucuronide conjugates

Sulfate conjugates

Substrate
Methotrexate
Doxorubicin, daunorubicin, epirubicin, idarubicin
Etoposide
Vincristine, vinblastine
Irinotecan, SN-38, topotecan
Doxorubicin-SG
Cyclophosphamide-SG
Melphalan-SG
Leukotriene C4
PGA2-SG, PGJ2-SG
Etoposide-Gluc
SN-38-Gluc
E217βG
Glucuronosylbilirubin
Estrone-3-sulfate
Dehydroepiandrosterone sulfate

Source: Deeley RG and Cole SP. Substrate recognition and transport by multidrug
resistance protein 1 (ABCC1), FEBS Lett, 580: 1103-1111, 2006.
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to examine the contribution of each gene to basal drug resistance to a panel of drugs
including topotecan and SN-38 (101). In Mdr1a/1b null MEFs, a small (but significant)
increase was observed in sensitivity to topotecan and SN-38. However, a much larger
increase in topotecan and SN-38 sensitivity was observed in the triple knockout MEFs
(Mrp1 and Mdr1a/1b null). Therefore, the camptothecin analogs are better substrates for
MRP1 than Pgp.
1.3.2.2 MRP1 expression in neuroblastoma
Because MRP1 transports multiple drugs used in neuroblastoma therapy including
the camptothecin analogs, the relationship between MRP1 expression in neuroblastoma
and outcome has been examined. Norris and colleagues used RT-PCR to determine the
MRP1 mRNA expression in 60 primary, untreated neuroblastomas (10). Patients who
received chemotherapy were treated with regimens including the MRP1 substrates
vincristine and doxorubicin. The cumulative survival rate was higher in patients with low
MRP1 expression than in those with high expression (94% vs. 57%, respectively,
P<0.001, log-rank test). The 5-year event-free survival (EFS) rate was also higher in
patients with low MRP1 expressing tumors than in those with high expression (46% vs.
91%, respectively).
The same group confirmed these findings in a large prospective study of 209
neuroblastoma samples using RT-PCR (12). When all patients were evaluated based upon
MRP1 expression level, 5-year EFS was significantly higher in patients with low MRP1
expressing tumors in comparison to high MRP1 expression (76% vs. 40%, P< 0.001, logrank test).
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High MRP1 expression remained a significant predictor of outcome in three
subsets of patients. First, in patients with localized disease, those with high MRP1 had
worse EFS than those with low expression (56% vs. 90%, P= 0.001, log-rank test). Next,
children with MYCN nonamplified tumors and high MRP1 had worse EFS than those
with low expression (46% vs. 81%, P<0.001, log-rank test). Finally, in children with
stage 4 disease high MRP1 was associated with extremely poor EFS compared to those
with low expression (14% vs. 44%, P < 0.001, log-rank test). Therefore, even in patients
with favorable prognostic features such as localized disease or nonamplified MYCN,
MRP1 expression may be a useful indicator of prognosis that can be used to guide
therapy.
MRP1 mRNA expression is a prominent feature in neuroblastoma and may be a
strong, independent indicator of poor prognosis. However, due to the essentially
ubiquitous MRP1 expression in normal tissue, modulation of tumor-specific MRP1mediated resistance presents a significant challenge. However, the relationship between
MRP1 expression in neuroblastoma and poor prognosis may not be solely attributed to
drug efflux. As MRP1 expression is strongly correlated with MYCN amplification, the
expression of this ABC transporter may be a surrogate marker for another currently
unidentified MYCN target gene responsible for poor prognosis. Furthermore, these studies
have focused on the MRP1 mRNA expression, and therefore the question remains about
the mechanistic implications of the strong correlation between MYCN amplification and
MRP1 mRNA expression. It has not yet been determined whether MRP1 and MYCN
have independent roles in neuroblastoma. A mechanistic explanation for the poor
prognosis in patients with high MRP1 expression remains to be elucidated.
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1.3.3

MRP2
The human ABCC2 gene contains 32 exons (102) mapping to chromosome 10q24

and encodes a 180 kDa protein with alternative nomenclature that includes cMOAT (for
canalicular multispecific organic anion transporter) and MRP2 (multidrug resistance
associated protein 2). The MRP2 protein sequence is 48% homologous to MRP1 (103).
MRP2 is primarily expressed in the hepatocyte canalicular membrane and mediates the
hepatobiliary excretion of organic anions including glutathione and bilirubin
glucuronides (104). MRP2 expression has also been demonstrated at the apical membrane
of the renal proximal tubules (105).
1.3.3.1 MRP2 substrates
As with Pgp and MRP1, there is considerable overlap in substrate specificity
between MRP1 and MRP2. MRP2 substrates include vincristine, vinblastine,
methotrexate,

cisplatin,

doxorubicin,

epirubicin,

etoposide,

cyclophosphamide,

irinotecan, and SN-38 (106,107,108). MRP2 both transports and confers resistance to
irinotecan and SN-38. First in the HepG2 hepatic cancer cell line expressing MRP2,
antisense RNA to MRP2 reduced MRP2 expression and increased sensitivity to both
irinotecan and SN-38 (106). Chu and colleagues used canalicular membrane vesicles
isolated from rats to demonstrate the ATP-dependent transport of both the lactone and
carboxylate forms of SN-38G and the carboxylate forms of irinotecan and SN-38 (109).
1.3.3.2 MRP2 in neuroblastoma
To date MRP2 protein expression has not been demonstrated in neuroblastoma.
Norris and colleagues have demonstrated that MRP2 mRNA levels in patients with
neuroblastoma did not discriminate between treatment success or failure, but analysis of
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MRP2 protein expression was not reported (110). However, due to MRP2-mediated
transport of drugs used in neuroblastoma therapy including irinotecan/SN-38, vincristine,
cisplatin, and doxorubicin, MRP2 protein expression should be further evaluated in
neuroblastoma. Although neuroblastoma does not arise from a tissue that normally
expresses MRP2, expression of MRP2 in neuroblastoma is possible. Due to the potential
for efflux of irinotecan and SN-38 in MRP2-expressing tumor cells, if MRP2 is expressed
in neuroblastoma, the relationship between MRP2 expression and response to therapy
including MRP2 substrates should be explored.

1.3.4

MRP4
The human ABCC4 gene maps to chromosome 13q32 (111) and encodes the 170

kDa protein MRP4 (112). The organic anion transporter MRP4 was first identified in
1997 by searching the human expressed sequence tag (EST) database for sequences
homologous to the 3’-ends of MRP1 and MRP2 (113). Human MRP4 mRNA expression
was demonstrated in lung, kidney, bladder, and gall bladder and in drug resistant cell
lines derived from several tumor types including non-small cell lung cancer, small cell
lung cancer, lung adenocarcinoma, and promyelocytic leukemia. Tissue distribution
studies have shown that MRP4 is also expressed in the adrenal gland, on the apical side
of renal proximal tubules and capillaries in the brain, and the basolateral side of the
choroid plexus epithelium (114,115,116).
1.3.4.1 MRP4 substrates
MRP4 is an organic anion transporter, and its substrates include both xenobiotics
and endogenous substances. MRP4 was identified as a transporter of the nucleoside
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analog 9-(2-phosphonylmethoxyethyl) adenine (PMEA) (111). Inverted membrane
vesicles were used to identify the endogenous MRP4 substrates cGMP, cAMP, and
estradiol 17-β-D-glucuronide (E217βG) (117). Prostaglandin E1 (PGE1) and PGE2 have
also been identified as endogenous substrates (118). MRP4 also effluxes 6mercaptopurine (6-MP) monophosphates, 6-thioguanine (6-TG) monophosphates, and
methotrexate (117,119) and confers resistance to cyclophosphamide, but not etoposide, 5fluorouracil, carboplatin, vincristine, vinblastine, or paclitaxel (120).
Topotecan is an MRP4 substrate (114). In particular, increasing topotecan
concentrations reduced ATP-dependent uptake of E217βG into inverted membrane
vesicles overexpressing MRP4. Also, Saos2 cells overexpressing MRP4 were 5 times
more resistant to topotecan and accumulated less topotecan intracellularly than the
parental cell line.
Subsequently Tian and colleagues used stably transfected HepG2 (which
endogenously expresses MRP4 (121)) cells overexpressing MRP4 to demonstrate that
MRP4 confers resistance to other camptothecin analogs (120). Cells overexpressing
MRP4 were 3- to 6-fold resistant to irinotecan lactone. MRP4 conferred 8- to 9-fold
resistance to SN-38 lactone and carboxylate. The level of resistance to SN-38 and
irinotecan was similar to that observed for the classical MRP4 substrates bis-POMPMEA and methotrexate. Furthermore, this increase in resistance to both SN-38 and
irinotecan was accompanied by a 2- to 4-fold reduction in intracellular accumulation of
both irinotecan and SN-38.
Using the same MRP4 overexpressing HepG2 cell line, Tian and colleagues also
confirmed that MRP4 transports and confers resistance to topotecan (122). MRP4
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overexpression conferred 12-fold resistance to topotecan. The level of topotecan
resistance in MRP4 overexpressing cells was similar to that for bis-POM-PMEA. In
addition, topotecan intracellular accumulation was reduced in the MRP4 overexpressing
cells. Due to the endogenous MRP4 expression in the HepG2 cell line, these data provide
information about the contribution of overexpressed MRP4 to camptothecin analog
transport and resistance. The data do not give information about the level of resistance
conferred by the basal level of MRP4 expression. To determine the contribution of basal
MRP4 expression, the gene could be silenced using RNAi. Alternatively, if an inhibitor
specific for MRP4 (and not other ABC transporters) existed, it could be used to assess the
contribution of MRP4 to camptothecin analog transport and resistance.
1.3.4.2 MRP4 in neuroblastoma
Norris and colleagues reported that MRP4 mRNA expression was correlated with
MYCN amplification in neuroblastoma and was an independent predictor of poor
outcome (110). Although MYCN has not yet been shown to activate MRP4 transcription,
the MRP4 promoter contains an E box. Therefore, MRP4 may be a MYCN target gene.
In addition, MRP4 may confer clinical resistance to drugs used in neuroblastoma therapy,
notably the camptothecin analogs. Hence, the contribution of MRP4 expression to
camptothecin analog resistance in neuroblastoma will be explored in this project.

1.3.5

BCRP
The breast cancer resistance protein (BCRP) is the product of the ABCG2 gene

and maps to chromosome 4q22. BCRP aliases include MXR (for mitoxantrone
resistance) and ABCP for (placental ABC transporter). BCRP was identified by Doyle
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and colleagues in MCF7AdrVp, a breast cancer cell line selected for doxorubicin
resistance that did not express Pgp or MRP1 (123). At the same time Allikmets and
colleagues demonstrated BCRP expression in the placenta (124). Shortly thereafter,
Maliepaard and colleagues demonstrated BCRP overexpression in an ovarian cancer cell
line selected for topotecan resistance (125). BCRP is comprised of 663 amino acids and a
single NBD at the amino terminus. BCRP domains are organized NH2-NBD-TMDCOOH, giving the appearance of a half-transporter in contrast to Pgp and MRP (NH2TMD-NBD1-TMD-NBD2-COOH) (123). However, BCRP homodimerization is required
for function (126).In addition to expression in placental syncytiotrophoblasts, BCRP is
also expressed in the apical membrane of the small intestine epithelium, bile canaliculi,
and the apical membrane of endothelial cells in brain vasculature (127).
1.3.5.1 BCRP substrates
BCRP transports a variety of xenobiotics and endogenous substrates (Table 1.8).
Specifically, several studies have demonstrated that BCRP has a role in camptothecin
analog resistance. The majority of data addressing the substrate specificity of each
transporter has been generated using drug selected cell lines. Reduced accumulation and
increased resistance to topotecan and SN-38 have been demonstrated in BCRP
overexpressing cell lines selected for drug resistance (125,128). Because this selection
process can produce numerous genetic and post-translational alterations, the most reliable
substrate specificity data is generated in isogenic systems. Houghton and colleagues
demonstrated that Saos2 cells transfected with ABCG2 and overexpressing BCRP are 12fold and 50-fold more resistant to topotecan and SN-38, respectively, than the vector
control cell line (129). All of these studies taken together indicate that BCRP confers
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Table 1.8

Partial list of BCRP substrates.

Xenobiotic Substrates

Endogenous Substrates

Mitoxantrone

E217βG

Topotecan

Estrone-3-sulfate

Irinotecan, SN-38, SN-38 glucuronide

Dehydroepiandrosterone

Methotrexate, methotrexate
polyglutamates
Source:
Litman T, et al. The multidrug-resistant phenotype associated with
overexpression of the new ABC half-transporter, MXR (ABCG2), J Cell Sci, 113 ( Pt
11): 2011-2021, 2000.

resistance to the camptothecin analogs SN-38 and topotecan.
1.3.5.2 BCRP in neuroblastoma
The role of BCRP expression in neuroblastoma has not been studied extensively.
In one study of the mRNA expression of ABC transporters in neuroblastoma, BCRP
mRNA was detected in neuroblastoma tumor specimens from patients, but the level of
mRNA expression was not related to treatment outcome (110). The only other study of
BCRP expression in neuroblastoma used immunohistochemistry to demonstrate BCRP
protein expression in the xenograft NB1691 (130). Therefore, the extent to which BCRP
is expressed in neuroblastoma tumors in children and its role in response to camptothecin
analogs is unknown.
In summary, BCRP plays a role in camptothecin analog tumor resistance.
Therefore, the contribution of BCRP to camptothecin analog resistance in neuroblastoma
will be explored in this project.
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1.3.6

Modifying ABC transporter function
To determine the role of ABC transporters in drug resistance, the function and/ or

expression of the transporter must be modulated. A small molecule chemical modulator
can be used to inhibit transport or compete with substrates. Table 1.9 contains a partial
list of small molecule chemical modulators of ABC transporters. However, no small
molecule chemical inhibitor exists that inhibits a single ABC transporter. These chemical
modulators of ABC transporters are therefore more useful in modulating the activity of a
variety of transporters rather than in studying the contribution of a single transporter to
resistance.
Other useful approaches to investigate the function of specific transporters in
neuroblastoma cells or normal tissues include gene knockout, RNA interference (RNAi),
and overexpression. Null models in which the gene for a specific ABC transporter has
been knocked out can be used both in vitro and in vivo. For example, differences in drug
sensitivity between knockout and wild type MEFs can be determined in vitro to
determine the contribution of basal ABC transporter expression in normal tissues (101).
Knockout mice can be compared to wild-type mice in pharmacokinetic studies. However,
this approach is laborious and expensive. Moreover, it does not directly test the function
of the human transporter in a human system such as a cell line derived from a human
tumor sample. Also, due to the variation in sensitivity of different tumor types to
cytotoxic drugs, the contribution of ABC transporters to drug resistance in a particular
tumor type should be studied in the tumor or cell line of interest.
Exogenous overexpression of ABC transporters is another useful tool for studying
ABC transporter function. This approach has been used consistently to identify
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Table 1.9
Drug
Verapamil
Quinidine
Valspodar
MK571
Gefitinib
GF120918
Indomethacin

Chemical modulators of ABC transporters.
Transporters Inhibited
Pgp, MRP1, MRP4
Pgp, MRP1, MRP2
Pgp, MRP1
MRP1, MRP2, MRP4,
MRP7
Pgp, BCRP
Pgp, BCRP
MRP1, MRP4

References
(18,131,132)
(18)
(18)
(133,134,112,135)
(130,136)
(137,138,139,140)
(141,118,112)

Sources: Litman T, et al. From MDR to MXR: new understanding of multidrug
resistance systems, their properties and clinical significance, Cell and Molecular Life
Sciences, 58: 931-959, 2001.
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endogenous and xenobiotic substrates and to demonstrate multi-drug resistance. Cell
lines overexpressing ABC transporters have the advantage over those with basal
expression levels in that differences in substrate accumulation or resistance are more
pronounced and easily detected. However, due to protein abundance this approach does
not give much information about the role of normal, basal protein expression.
RNA interference (RNAi) can be used to silence the expression of a specific gene.
Just as for targeting the disruption of a particular gene locus to knock out a gene, RNAi
can be used to study the contribution of basal gene expression to the phenotype of
interest.
RNAi was first described as double-stranded RNA (dsRNA) mediated sequencespecific post transcriptional gene silencing in the nematode Caenorhabditis elegans
(142). The highly conserved RNAi phenomenon of gene silencing has been observed in
protozoa, invertebrates, vertebrates, plants, fungi, and algae. RNAi is hypothesized to
serve as an antiviral defense mechanism (143,144).
Experimentally, RNAi can be used to reduce or eliminate the expression of a
protein by targeting its mRNA for degradation. Dicer, an RNase III-like enzyme cleaves
long dsRNA molecules into 21- to 23-nucleotide small interfering RNAs (siRNAs) (145).
Subsequently the siRNAs are incorporated into the RNAi-induced silencing complex
(RISC). ATP activates the RISC complex to expose the antisense siRNA strand and bind
the targeted complementary mRNA (146). Finally, the mRNA is degraded by
exonucleases (147,148). Exogenously delivered RNAi used to inhibit ABC transporter
function has an advantage over chemical inhibition due to specific targeting of a single
gene.
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Despite the ability to achieve targeted silencing of a single gene based upon
nucleotide sequence complementarity, RNAi can induce nonspecific off-target effects
that include the interferon response and concentration-dependent induction of off-target
genes(149). The interferon response elicited by introduction of long dsDNA can be
circumvented by introduction of siRNAs, which are short dsDNA molecules 21-22 bp in
length that specifically target degradation of mammalian genes. Using the minimum
effective siRNA concentration eliminates the induction of off-target or “siRNAresponse” genes (150).
To achieve gene silencing with RNAi, the construct must be appropriately
delivered to the target cell and can be transient or stable. RNAi can be delivered as small
interfering RNA (siRNA) or short hairpin RNA (shRNA) oligonucleotides to achieve
transient knockdown of a gene. Plasmids or retroviral vectors containing a shRNA
cassette under the control of the RNA polymerase promoter (i.e., H1 or U6) can be used
to achieve stable expression of RNAi. Brummelkamp and colleagues achieved stable
RNAi by including a puromycin resistance cassette in a plasmid containing the H1
promoter and a 19-nt gene specific insert followed by a spacer to form a hairpin and then
the reverse complement of the 19-nt sequence (151). Therefore, stable retroviral mediated
RNAi will be used to silence ABC transporter expression in neuroblastoma cell lines to
determine the contribution of basal expression to in vitro and in vivo camptothecin analog
sensitivity.

1.4

Summary
High-risk neuroblastoma remains a significant clinical challenge despite

aggressive and intense therapy. The camptothecin analogs topotecan and irinotecan are
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useful components of neuroblastoma therapy. Despite a favorable anti-tumor response
rate to pharmacokinetically guided topotecan in children with high-risk neuroblastoma,
some patients failed to achieve a clinically meaningful response. Therefore, we postulate
that molecular mechanisms of drug resistance were also present in primary
neuroblastoma cells. Specifically we propose that Pgp, MRP1, MRP2, MRP4, and BCRP
may be expressed in neuroblastoma and may confer resistance to topotecan and
irinotecan/ SN-38. The primary hypothesis of this dissertation was that the expression of
ABC transporters contributes to clinical resistance of neuroblastoma to the cytotoxicity of
topotecan and irinotecan/ SN-38.

1.5

Specific aims
The primary objective of this work was to understand the role of ABC

transporters in neuroblastoma resistance to the camptothecin analogs. Potentially relevant
ABC transporters include Pgp, MRP1, MRP2, MRP4, and BCRP. To accomplish this
objective we will use genetically modified neuroblastoma cell lines, xenograft models,
and biopsy specimens from children with high-risk neuroblastoma.

1.5.1

To determine the contribution of ABC transporters to topotecan and irinotecan
sensitivity in neuroblastoma cell lines
A panel of neuroblastoma cell lines representing a range of topotecan and

irinotecan sensitivities will be evaluated to determine if differential expression of ABC
transporters identifies specific transporters that may confer clinical resistance to the
camptothecin analogs. RNAi will be used to silence MRP4 and Pgp in a resistant
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neuroblastoma cell line. In addition, MRP4 will be overexpressed in a sensitive
neuroblastoma cell line.

1.5.2

To determine the role of MRP4 in neuroblastoma xenograft response to
topotecan
A murine xenograft model in which MRP4 has been silenced via RNAi will be

established. Mice bearing neuroblastoma xenografts with silenced MRP4 will be treated
with topotecan to assess the contribution of basal MRP4 expression to topotecan
resistance in neuroblastoma in vivo.

1.5.3

To determine the role of ABC transporter expression in response to topotecan
in children with high-risk neuroblastoma
Immunohistochemistry will be used to characterize the ABC transporter

expression in neuroblastoma biopsy specimens from children with high-risk disease. The
association between ABC transporter expression and response to pharmacokinetically
guided topotecan will be evaluated.
In summary, a subset of children with high-risk neuroblastoma did not respond to
camptothecin analog based therapy. ABC transporters (e.g., MRP4 and Pgp) may
contribute to this clinical resistance. These in vitro, in vivo, and clinical studies of
neuroblastoma will help to define the role of MRP4 and Pgp in camptothecin analog
resistance in neuroblastoma.
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Chapter 2.

MRP4 and P-glycoprotein confer resistance to
topotecan in neuroblastoma

2.1

Introduction
Neuroblastoma is the most common extracranial solid tumor in children. The

prognosis for children diagnosed with high-risk neuroblastoma is poor, with 5-year
survival less than 30% (152). Topotecan and irinotecan anti-tumor activity in
neuroblastoma has been demonstrated in preclinical studies and phase I clinical trials,
including

studies

in

children

with

high-risk

disease

(64,66,70,71,17,76,153).

Furthermore, there is a steep topotecan systemic exposure/ anti-tumor response
relationship.

However,

substantial

interindividual

variation

in

topotecan

pharmacokinetics exists in children. Topotecan systemic clearance, the determinant of
systemic exposure as measured by AUC, varies at least ten-fold in children (49).
Therefore, dosing topotecan based solely on body surface area may lead to some antitumor responses but also a range of toxic and subtherapeutic exposures.
Minimizing interindividual variability in topotecan systemic exposure with a
pharmacokinetically guided dosing approach has been successful in terms of achieving
the putatively effective systemic exposure in children with high-risk neuroblastoma (15).
In a phase II trial this pharmacokinetically guided dosing approach also resulted in very
good anti-tumor activity. Out of 28 children with high-risk neuroblastoma evaluable for a
response to pharmacokinetically guided topotecan, 1 complete response and 17 partial
responses were observed. However, the ten children with tumors that failed to respond
may represent a subset of the disease resistant to topotecan (49,154,155).
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Although clinical resistance to topotecan is multi-factorial, ABC transporters have
been implicated in multi-drug resistance in neuroblastoma. Pgp and MRP1 have been
associated with diminished response of neuroblastoma to chemotherapy (52,156). Many
of the drugs used to treat neuroblastoma are MRP1 and/ or Pgp substrates, including
doxorubicin, vincristine, and etoposide. However, mechanistic studies validating a link
between protein expression of ABC transporters and resistance to chemotherapeutic
agents are lacking. Moreover, in neuroblastoma the expression of other members of the
ABC transporter superfamily such as MRP2, MRP4, and BCRP has not been well
characterized.
We have previously demonstrated that topotecan is an MRP4 substrate (114).
Topotecan, irinotecan, and SN-38 are BCRP substrates. Irinotecan and SN-38 are also
MRP2 substrates (125,157,158). Several investigators have demonstrated that Pgp
confers resistance to topotecan. In this study we used RNAi to reduce MRP4 and Pgp
expression in neuroblastoma cell lines to evaluate the effect of ABC transporters on
topotecan and irinotecan resistance.
RNAi can be mediated through siRNA or shRNA. Reductions in protein
expression mediated by siRNA are transient. In cell culture, this gene silencing persists
for 3-5 days (159). Variation in transfection efficiency also limits the application of
transient transfection of siRNA. Knock down via transient transfection of siRNA
targeting ABC transporters is suitable to test certain phenotypes such as drug
accumulation. However, this transient system is not suitable to test longer time-dependent
phenotypes such as drug sensitivity using the MTT assay.
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In contrast with transient siRNA-mediated downregulation of gene expression,
retroviral vector mediated shRNA can persist for long periods of time, due to integration
in the host genome. In addition, retroviral vectors can carry selection markers such as
puromycin resistance genes or green fluorescent protein (GFP). Continuous selection
pressure can be applied by culturing in the presence of puromycin. Alternatively, drug
interactions or non-specific effects of selection antibiotics can be avoided using GFP as a
selection marker. GFP expressing clones can be sorted by FACS, and GFP expression
over time can be monitored via flow cytometry or fluorescence microscopy. But in all
cases, reduced protein expression of the shRNA targeted gene must be confirmed.
Thus, the objectives of the present study were to determine whether MRP4 and
Pgp confer resistance to topotecan and SN-38 in neuroblastoma. Therefore, we used
shRNA to knock down MRP4 and Pgp expression in the cell line NB1691. Furthermore,
we overexpressed MRP4 in the cell line NB1643. These in vitro models were used to
evaluate intracellular drug accumulation and sensitivity to camptothecin analogs.

2.2

2.2.1

Materials and methods

Chemicals and cell lines
Topotecan,

3

H-topotecan, and

14

C-topotecan were generously provided by

GlaxoSmithKline (King of Prussia, PA). SN-38, the active component of the pro-drug
irinotecan (CPT-11) was provided by Pfizer (New York, NY).
NB1691, NB1643, SKNAS, SKNSH, NBEB (also known as SJNB1), and NBSD
(also known as SJNB4) cell lines were kindly provided by Dr. Peter Houghton (St. Jude
Children’s Research Hospital, Memphis, TN). Saos2 pcDNA and Saos2 MRP4 cell lines
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were kindly provided by Dr. John Schuetz (St. Jude Children’s Research Hospital). The
amphotropic retroviral packaging cell line Phoenix was obtained from ATCC (Manassas,
VA). Cells were maintained in RPMI 1640 (Mediatech, Herndon, VA), 10% FBS
(HyClone, Logan, UT), and 1% L-glutamine (Mediatech) at 37°C, 5% CO2.

2.2.2

Transient MDR1 siRNA
Three siRNA constructs targeting MDR1 (Ambion, Austin, TX) were transfected

(30 nM) into NB1691 using siPORT Amine (Ambion). The sequence targeting MDR1
exon 4 was selected for further use in stable shRNA studies, and the primers 5’-GATCCCCGGGAAAAGAAACCAACTGTCTCAAGAGGACAGTTGGTTTCTTTTCCCTTTTTGGAAA-3’ and 5’-AGCTTTTCCAAAAAGGGAAAAGAAACCAACTGTCCTCTTGAGACAGTTGGTTTCTTTTCCCGGG-3’ containing BglII and HindIII half-sites
were cloned into pSuper.

2.2.3

Stable RNAi by cloning MRP4 or MDR1 shRNA into MSCVGFP
The pSUPER42 (118) vector containing a MRP4 shRNA cassette was generously

provided by Dr. Piet Borst (Netherlands Cancer Institute, Amsterdam, Netherlands). The
MSCVGFP42 construct was made by cloning a SmaI and SalI fragment from pSUPER42
containing the H1 promoter and MRP4 shRNA sequence into SalI and HindIII sites of
MSCVGFP (160). The MSCV MDR1 shRNA GFP construct was made by cloning a
SmaI and SalI fragment from pSuperMDR1shRNA into the SalI and HindIII sites of
MSCVGFP. FuGENE6 (Roche Applied Science) was used to transfect MSCVGFP42,
MSCV MDR1 shRNA GFP, or MSCVGFP into Phoenix producer cells. Retrovirus was
harvested from Phoenix cells sorted for GFP expression, and NB1691 cells were
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transduced with vector alone, the MRP4 knockdown construct MSCVGFP42, or the Pgp
knockdown construct MSCV MDR1 shRNA GFP. Clones with stable MRP4 or Pgp
knockdown were generated by sorting single NB1691 cells expressing GFP into 96-well
plates, expanding, and screening by real-time RT-PCR and Western blot for MRP4 or
Pgp expression.

2.2.4

Cloning MRP4 into NB1643
The MRP4 expression vector MSCV MRP4 IRES GFP containing an internal

ribosomal entry site permitting co-expression of MRP4 and GFP (kindly provided by Dr.
John Schuetz) was transfected into Phoenix cells (161). NB1643 cells were transduced
with retrovirus harvested from cells sorted for GFP expression. NB1643 cells
overexpressing MRP4 were selected by FACS, expanded, and screened by Western blot
for MRP4 expression.

2.2.5

Real-time RT-PCR
RNA was extracted from cells with Tri-Reagent (Molecular Research Center,

Cincinnati, OH), and cDNA was synthesized using a mixture of oligo-dT and random
hexamer primers with the QuantiTect Reverse Transcription Kit (Qiagen, Valencia, CA).
Real-time PCR analysis was conducted using gene specific primers (Table 2.1) and
QuantiTect SYBR Green PCR Kit (Qiagen) on the ABI Prism 7900HT (Applied
Biosystems, Foster City, CA). Thermal cycling conditions were as follows: 15 min at
95°C followed by 40 cycles of 95°C for 30 s, 60°C for 30 s, 72°C for 30 s, and finally a
denaturation stage. The mRNA expression level was determined by the comparative Ct
method. Fold-change in mRNA expression level was calculated by evaluating the
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Table 2.1

Primer sequences for real-time RT-PCR.

Gene

Primer Sense

Primer Antisense

Reference

MDR1

CTGTATTGTTTGCCACCACGA

AGGGTGTCAAATTTATGAGGCAGT

(162)

MRP4

CAGTACCTCAAAGCTGCAAGTC

CCCAGTATGAAAGCCACCAA

(163)

BCRP

CAGGAGGCCTTGGGATACTT

TGCCACAGCAGTGGAATCT

(164)

GAPDH

ACCACAGTCCATGCCATCAC

TCCACCACCCTGTTGCTGTA

(163)

β-actin

GAGCACAGAGCCTCGCCTTT

TGACCCATGCCCACCATCAC

Sources: Wunderlich K, et al. Vasospastic persons exhibit differential expression of
ABC-transport proteins, Mol Vis, 9: 756-761, 2003.
Assem M, et al. Interactions between hepatic Mrp4 and Sult2a as revealed by the
constitutive androstane receptor and Mrp4 knockout mice, J Biol Chem, 279: 2225022257, 2004.
Zamber CP, et al. Natural allelic variants of breast cancer resistance protein (BCRP) and
their relationship to BCRP expression in human intestine, Pharmacogenetics, 13: 19-28,
2003.
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expression 2-ΔΔCt where Ct is the cycle threshold, ΔCt is the difference in mean cycle
threshold between the gene of interest and the normalizing gene (e.g., Ct MRP4-Ct

GAPDH),

and ΔΔCt is the difference between the ΔCt’s of the reference and test samples (e.g., ΔCt
NB1691 -

ΔCt NB1691 4.27).

2.2.6

Western blot
Membrane enriched fractions were isolated from cells by sonicating in

homogenizing buffer (100 mM Tris-HCl, 100 mM KCl, 1 mM EDTA, and protease
inhibitors, Roche Applied Science, Indianapolis, IN) and centrifugation at 18,000 x g for
15 min. The pellet was resuspended in microsome storage buffer (100 mM KH2PO4, 1
mM EDTA, 20% glycerol, and protease inhibitors), and DNA was sheared by passing
through a 27 gauge needle. In some cases, membrane proteins were isolated using the
Mem-PER Eukaryotic Membrane Protein Extraction Kit (Pierce, Rockford, IL).
Detergents used in the Mem-PER protein isolation were removed using the PAGEprep
Advance Clean-Up Kit (Pierce).
Protein was quantitated by Bradford Assay (Bio-Rad, Hercules, CA). Proteins (10
μg per lane) were separated by SDS-PAGE (4-12% Bis-Tris gel, MOPS running buffer,
Invitrogen, Carlsbad, CA) and transferred to PVDF membranes. Blots were probed with
the polyclonal rabbit-anti-human MRP4, kindly provided by Dr. John Schuetz, or the
monoclonal antibodies M4I-10 (rat anti-human and mouse MRP4, Axxora, San Diego,
CA), BXP-21 (mouse anti-human BCRP, Kamiya Biomedical, Seattle, WA), AC-15
(mouse anti-human β-actin, Sigma, St. Louis, MO), and JSB-1 (mouse anti-human Pgp,
Signet Labs, Dedham, MA). Proteins were visualized with ECL Plus (Amersham
Biosciences, Piscataway, NJ).
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Membrane samples that appeared to express MRP4 with a higher molecular
weight than the positive control were treated with the enzyme PNGaseF (New England
Biolabs, Ipswich, MA) to deglycosylate proteins. For this reaction, 10μg of membrane
protein were denatured in the reaction buffer for 10 min at 37°C. Then 500 units
PNGaseF was added for a 1 hr incubation at 37°C.

2.2.7

Intracellular topotecan, PMEA, rhodamine 123, and mitoxantrone
accumulation
Neuroblastoma cells were plated in 6-well plates (300,000 cells/well) in media

without phenol red and allowed to attach overnight. 3H-topotecan or

14

C-topotecan was

added (final concentration of 10 μM, 3H-topotecan specific activity 100 dpm/pmol and
14

C-topotecan specific activity 30 dpm/pmol) for 6 hr at 37°C. MRP4 function was

assessed

by

PMEA

intracellular

accumulation.

Bis(POM)3H-PMEA

(Moravek

Biochemicals, Brea, CA) was added (10 μM) and incubated at 37°C for 20 hr. The media
was removed, and cells were washed once in ice-cold PBS. Cells were detached by
addition of 0.5 N NaOH and acidified with 1 N HCl. Intracellular 3H-topotecan,

14

C-

topotecan, or 3H-PMEA was measured by scintillation counting with normalization to
total protein content.
Pgp function was assessed by intracellular rhodamine accumulation in 106
neuroblastoma cells incubated for 30 min with 0.1 mg/mL rhodamine 123 (165).
Intracellular fluorescence was determined by FACS. Pgp function in cells expressing
GFP, which fluoresces in the same channel as rhodamine 123, was assessed by
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intracellular 3H-mitoxantrone (Moravek Biochemicals) accumulation, as described for
radiolabeled topotecan and PMEA.

2.2.8

MTT assay
Cells were plated in RPMI 1640 without phenol red, 10% FBS, and 1% L-

glutamine in 96-well plates (10,000 cells/well) and allowed to attach overnight. Cells
were exposed to various concentrations of topotecan (1 nM to 200 μM) or SN-38 (1 nM
to 100 μM) for 6 hr, and the media was replaced. Viability was assessed 4 days later by
the addition of MTT (Sigma, St. Louis, MO) for 3 hr. Formazan crystals produced only
by viable cells were solubilized with 0.04 N HCl in isopropanol. Absorbance was
measured at 570 nm with wavelength correction at 650 nm on the μQuant Microplate
Spectrophotometer (Bio-Tek Instruments, Winooski, VT).

2.2.9

Statistical considerations
The drug concentration that inhibited 50% of cell growth (IC50) was calculated

according to the Michaelis-Menten equation. Student’s t-test with Bonferroni correction
was used to determine differences in IC50 between control and transduced neuroblastoma
cell lines. Dunnett’s multiple comparison tests was used to determine differences in
intracellular drug accumulation between control and transduced neuroblastoma cell lines.
All tests were two-tailed.
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2.3

2.3.1

Results

Functional MRP4 and Pgp expression in neuroblastoma cell lines resistant to
camptothecin analogs
Since expression of ABC transporters confers resistance to topotecan and

irinotecan/SN38, we evaluated the expression of Pgp, MRP1, MRP2, MRP4, and BCRP
in six neuroblastoma cell lines. We determined that MRP1 was expressed in all
neuroblastoma cell lines representing a spectrum of sensitivity to topotecan. In contrast,
neither MRP2 nor BCRP was expressed in vitro in these six neuroblastoma cell lines.
Next, we determined that both MRP4 and Pgp were differentially expressed in the six
neuroblastoma cell lines (Figure 2.1). Both MRP4 and Pgp were expressed in NB1691.
However, neither MRP4 nor Pgp were expressed in NB1643. SKNAS also expressed
MRP4 but not Pgp. SKNSH expressed Pgp but not MRP4.
We also measured intracellular accumulation of the MRP4 substrate PMEA
(Figure 2.2A). NB1691 and SKNAS, the two cells lines that expressed MRP4, exhibited
the lowest intracellular PMEA accumulation, consistent with the hypothesis that MRP4
was functionally active and effluxing PMEA. In contrast, NB1643 accumulated the
highest level of intracellular PMEA.
Likewise, to demonstrate functional expression of Pgp, we measured intracellular
accumulation of the Pgp substrate rhodamine 123 (Figure 2.2B). The two Pgp expressing
cell lines NB1691 and SKNSH accumulated the least rhodamine intracellularly,
suggesting the presence of a functionally active efflux transporter. The highest rhodamine
accumulation was observed in NB1643, consistent with the lack of an efflux transporter.
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Figure 2.1
lines.

MRP4 and Pgp expression in topotecan resistant neuroblastoma cell

The blot was probed with polyclone rabbit-anti-human MRP4 antibody. The negative and
positive controls are from Saos2 pcDNA and Saos2 MRP4 cell lysates, respectively.
MRP4 is expressed in NB1691 and SKNAS. The lower molecular weight band present in
all samples is a non-specific band. Pgp is expressed in NB1691 and SKNSH. NB1643
expresses neither MRP4 nor Pgp.
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Figure 2.2
Accumulation of the MRP4 and Pgp substrates PMEA and
rhodamine 123 in neuroblastoma cell lines.
PMEA accumulation is the lowest in the MRP4 expressing cell lines in NB1691 and
SKNAS. The highest PMEA accumulation was observed in NB1643, which does not
express MRP4 (A). Pgp expression in NB1691 and SKNSH leads to reduced intracellular
accumulation of rhodamine 123. The highest rhodamine accumulation occurs in NB1643,
which lacks Pgp expression (B).
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To evaluate whether the expression of ABC transporters was related to topotecan
sensitivity in this panel of six neuroblastoma cell lines, we determined the IC50 to a six hr
topotecan exposure by MTT assay. The topotecan IC50 was 8 μM for NB1691 and 0.4
μM for NB1643 (Figure 2.3A). This 20-fold increased topotecan resistance in NB1691 is
accompanied by reduced topotecan intracellular accumulation (Figure 2.3B) in NB1691
compared to NB1643, consistent with drug efflux as a resistance mechanism in NB1691.
The next highest topotecan IC50 was observed in SKNSH, which expressed Pgp but not
MPR4.

2.3.2

Functional MRP4 knockdown with stably expressed shRNA
Due to MRP4 and Pgp expression in the two neuroblastoma cell lines most

resistant to topotecan, and a lack of MRP4 or Pgp expression in the neuroblastoma cell
line most sensitive to topotecan, we took two approaches to determine the relative
contribution of MPR4 or Pgp to resistance. First, we used RNAi to reduce the expression
of either MRP4 or Pgp in NB1691 and determine if there was an increase in sensitivity to
the camptothecin analogs. The second approach to determine the contribution of MRP4
to camptothecin analog sensitivity was to overexpress MRP4 in NB1643 and determine if
there was an increase in resistance to camptothecin analogs.
Using retroviral mediated expression of MRP4 shRNA, both MRP4 protein and
mRNA expression were reduced in NB1691 GFP4.2 clones 7 and 9 compared to both the
parental and vector only cell lines (Figure 2.4, Figure 2.5). Functional knockdown of
MRP4 was confirmed by increased PMEA accumulation in NB1691 4.2 7 and 4.2 9
(Figure 2.6). Functional knockdown of MRP4 resulted in increased sensitivity to
topotecan 4-fold and 2-fold in clones 4.2 7 and 4.2 9, respectively (Figure 2.7).
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H-Topotecan sensitivity and accumulation in neuroblastoma cell

The topotecan IC50 determined by MTT assay after a 6 hr exposure to the drug is 8 μM
for NB1691 and 0.4 μM for NB1643 (A). Less 3H-topotecan accumulates intracellularly
in the resistant NB1691 compared NB1643 (B).
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Saos2 MRP4
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Figure 2.4
Immunoblot analysis of MRP4 expression in NB1691 cells transduced
with MRP4 shRNA.
MRP4 expression was reduced in the NB1691 clones transduced with the retrovirus
carrying the MRP4 shRNA and GFP cassettes. β-actin expression is depicted as the
loading control.
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Figure 2.5

GFP1

4.2 7

4.2 9

Real-time RT-PCR analysis in NB1691 MRP4 shRNA clones.

MRP4 mRNA expression is reduced in clones 4.2 7 and 4.2 9 compared to the parental
cell line and vector control. Values are presented as mean ± standard deviation.* P≤ 0.01
(t-test with Bonferroni correction).
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Figure 2.6

GFP1

4.2 7

4.2 9

PMEA intracellular accumulation in NB1691 MRP4 shRNA clones.

Intracellular PMEA accumulation was determined after a 20 hr incubation with BisPOM-PMEA. Reduced MRP4 expression in clones 4.2 7 and 4.2 9 results in an increase
in PMEA intracellular accumulation, indicating functional knockdown of MRP4. Values
are presented as mean ± standard deviation. * P≤ 0.001 (Dunnett’s test).
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Figure 2.7

Topotecan sensitivity in NB1691 MRP4 shRNA clones.

Viability curve derived from MTT assay of NB1691 and clones with reduced MRP4
expression demonstrates increased topotecan sensitivity in clones 4.2 7 and 4.2 9. The 6
hr topotecan IC50 is lower in NB1691 clones with reduced MRP4 expression compared to
the parental cell line (inset). Viability is presented as mean ± standard deviation with the
best fit line. IC50 values are presented as mean IC50 estimate (95% confidence interval)
(B). * P≤ 0.01 (t-test with Bonferroni correction).
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Furthermore, knocking down MRP4 expression resulted in 2-fold increased SN-38
sensitivity in clones 4.2 7 and 4.2 9 (Figure 2.8). We also evaluated the sensitivity to the
prodrug irinotecan in the clones with reduced MRP4 expression, but there was no
difference between the parental control and clones 4.2 7 and 4.2 9 (data not shown).

2.3.3

Functional MRP4 overexpression in NB1643
After demonstrating that topotecan and SN-38 sensitivity increased upon

reduction of MRP4 expression, we evaluated the effect of MRP4 overexpression in
NB1643. MRP4 protein levels were 1.4- fold higher in NB1643 MRP4 IRES GFP
compared to the parental cell line, as determined by densitometry (Figure 2.9). These
samples were subjected to enzymatic deglycosylation because we observed slight
variation in MRP4 electrophoretic migration between NB1643 and the Saos2 control
cells. We reasoned that the observed differences in MRP4 molecular weight among cell
lines may be due to differential glycosylation. Protein band intensity increased upon
deglycosylation with PNGaseF, indicating that the M4I-10 antibody may have more
specificity for deglycosylated MRP4 than the native glycoprotein.
MRP4 expression in NB1643 resulted in reduced intracellular accumulation of
PMEA, indicating the presence of functional MRP4 (Figure 2.10A). PMEA accumulation
in NB1643 MSCV MRP4 IRES GFP was 20% lower than in NB1643 (P≤0.01),
proportional to the MRP4 expression level. In the Saos2 MRP4 control cell line, PMEA
accumulation was 2-fold lower than the vector control (Figure 2.10B). Functional
expression of MRP4 in NB1643 resulted in an increase in camptothecin analog
resistance. The 6 hr topotecan IC50 was 7-fold higher in NB1643 MRP4 compared to
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Figure 2.8

SN38 sensitivity in NB1691 MRP4 shRNA clones.

Viability curve derived from MTT assay of NB1691 and clones with reduced MRP4
expression demonstrates increased SN-38 sensitivity in clones 4.2 7 and 4.2 9. The 6 hr
SN-38 IC50 is lower in NB1691 clones with reduced MRP4 expression compared to the
parental cell line (inset). Viability is presented as mean ± standard deviation with the best
fit line. IC50 values are presented as mean IC50 estimate (95% confidence interval). * P≤
0.01 (t-test with Bonferroni correction).
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Figure 2.9
Immunoblot analysis of MRP4 expression in NB1643 cells transduced
with MSCV MRP4 IRES GFP.
The blot was probed with the monoclonal M4I-10 antibody. MRP4 is overexpressed in
NB1643 cells transduced with MSCV MRP4 IRES GFP. PMEA accumulation is reduced
in cells overexpressing MRP4. Sensitivity to topotecan and SN-38 decreases in NB1643
cells overexpressing MRP4.
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MRP4 overexpression in NB1643 results in 20% decrease in intracellular PMEA
accumulation, indicating the presence of a functional efflux transporter (A). PMEA
accumulation in the control Saos2 cell line was reduced 2-fold in the MRP4
overexpressing cell line Saos2 MRP4 (B). Values are presented as mean ± standard
deviation.* P≤ 0.005 (Dunnett’s multiple comparison test).
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NB1643 (Figure 2.11). The 6 hr SN-38 IC50 was 1.5-fold higher in NB1643 MRP4
compared to NB1643 (Figure 2.12).

2.3.4

Functional Pgp knockdown with stably expressed shRNA
Based upon the preliminary screen of six neuroblastoma cell lines in which Pgp

was expressed in the most resistant cell line to topotecan, we also evaluated the effect of
reducing Pgp expression in NB1691. The shRNA construct targeting MDR1 mRNA for
degradation resulted in a significant decrease in MDR1 expression in clones 1, 2, and 3
(Figure 2.13).
Intracellular mitoxantrone accumulation was used to assess functional Pgp
knockdown in the NB1691 MDR1 shRNA clones. Rhodamine 123 could not be used as a
probe for Pgp function because rhodamine 123 and GFP fluoresce in the same channel. In
the Pgp overexpressing cell line LLCPK1 MDR1, mitoxantrone accumulation was
significantly reduced compared to LLCPK1, consistent with mitoxantrone as a Pgp
substrate. Mitoxantrone accumulation was significantly higher (2-fold) in NB1691
MDR1 shRNA clones 1, 2, and 3 than in the parental NB1691, consistent with reduced
Pgp function (Figure 2.14). Furthermore, topotecan accumulated intracellularly at higher
levels in MDR1 shRNA clones 1 and 3 (Figure 2.15A). Further confirming topotecan as a
Pgp substrate, topotecan accumulation was reduced in the Pgp overexpressing LLCPK1
MDR1 in comparison to the vector control (Figure 2.15B). Finally, the reduction in Pgp
function and increased topotecan accumulation resulted in increased sensitivity to
topotecan. The topotecan IC50 was 2- to 5-fold lower than NB1691 in MDR1 shRNA

70

120

NB1643
NB1643 IRES
NB1643 MRP4

80
1.6

40

*

1.4

60
Topotecan IC50 (μM)

Viability (% Vehicle Control)

100

20

1.2
1.0
0.8
0.6
0.4
0.2
0.0

0
0.0001

NB1643

0.001

IRES

0.01

MRP4

0.1

1

10

100

1000

Topotecan Concentration (μM)

Figure 2.11

Topotecan sensitivity in NB1643 cells overexpressing MRP4.

Viability curve derived from MTT assay of NB1643, NB1643 IRES, and NB1643 MRP4
demonstrates reduced topotecan sensitivity in the cell line overexpressing MRP4. The 6
hr topotecan IC50 is significantly higher in NB1643 MRP4 compared to the parental cell
line (inset). Viability is presented as mean ± standard deviation with the best fit line. IC50
values are presented as mean IC50 estimate (95% confidence interval). * P≤ 0.01 (t-test
with Bonferroni correction).
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Figure 2.12

SN-38 sensitivity in NB1643 cells overexpressing MRP4.

Viability curve derived from MTT assay of NB1643, NB1643 IRES, and NB1643 MRP4
demonstrates reduced SN-38 sensitivity in the cell line overexpressing MRP4 (mean ±
standard deviation, best fit line). The 6 hr SN-38 IC50 is significantly higher in NB1643
MRP4 compared to the parental cell line. Values are presented as mean IC50 estimate
(95% confidence interval) (B). * P≤ 0.01 (t-test with Bonferroni correction).
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Real-time RT-PCR analysis of in NB1691 MDR1 shRNA clones.

MDR1 mRNA expression is reduced in clones 1, 2, and 3 compared to the parental cell
and vector control. Values are presented as mean ± standard deviation.* P≤ 0.01 (t-test
with Bonferroni correction).
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Reduced Pgp expression in MDR1 shRNA clones 1 and 3 results in an increase in
topotecan intracellular accumulation (A). Topotecan accumulation is significantly
reduced in the Pgp overexpressing cell line LLCPK1 MDR1 (B). Values are presented as
mean ± standard deviation. * P≤ 0.001 (Dunnett’s multiple comparison test).

75

clones 2 and 3 (Figure 2.16). However, reduced Pgp expression and function did not
result in increased sensitivity to SN-38 (Figure 2.17). To determine if this unexpected
phenotype was related to an increase in expression of other ABC transporters such as
MRP2, we used real-time RT-PCR to evaluate mRNA expression. However, MRP2 was
expressed at low levels in all of the cell lines, and no statistically significant difference
was noted in expression level among the cell lines (data not shown).

2.4

Discussion
In this study we have shown that ABC transporter expression confers

camptothecin analog resistance in neuroblastoma cell lines. Furthermore, reducing ABC
transporter expression via shRNA reduces camptothecin analog resistance. The ABC
transporters MRP4 and Pgp, which confer resistance to topotecan and SN-38
(89,114,120,122), were expressed and functional in neuroblastoma cell lines relatively
resistant to topotecan. In contrast, MRP4 and Pgp were not expressed in NB1643, which
is relatively sensitive to topotecan. The differences in sensitivity to topotecan between
NB1643 and NB1691 are not likely due to p53 status because both of these cell lines are
wild-type p53 (166,167,168). These in vitro results are consistent with previous in vivo
xenograft studies in which NB1643 xenografts responded to a topotecan systemic
exposure of 52 ng/mL*hr (61). In contrast, a topotecan systemic exposure of 290
ng/mL*hr was required to achieve a complete response in NB1691 xenografts. The
results of the current study may explain the mechanisms of camptothecin analog
resistance in some neuroblastomas.
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Figure 2.16

Topotecan sensitivity in NB1691 MDR1 shRNA clones

Viability curve derived from MTT assay of NB1691 and MDR1 shRNA clones 2 and 3
demonstrates increased topotecan sensitivity in clones 2 and 3. The 6 hr topotecan IC50 is
statistically significantly lower in clones 2 and 3 expressing MDR1 shRNA compared to
the parental cell line (inset). Values are presented as mean IC50 estimate (95% confidence
interval) (B). * P≤ 0.01 (t-test with Bonferroni correction).
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Figure 2.17

SN-38 sensitivity in NB1691 MDR1 shRNA clones.

Viability curve derived from MTT assay of NB1691 and MDR1 shRNA clones 2 and 3
demonstrates increased SN-38 resistance in clone 3. The 6 hr topotecan IC50 is
statistically significantly higher in clone 3 expressing MDR1 shRNA compared to the
parental cell line (inset). Values are presented as mean IC50 estimate (95% confidence
interval) (B). * P≤ 0.01 (t-test with Bonferroni correction).
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The initial results of immunoblot analysis of ABC transporter expression in
neuroblastoma cell lines representing a spectrum of topotecan sensitivities indicated that
MRP4 and Pgp may be partly responsible for resistance to camptothecin analogs in
neuroblastoma. Therefore, to determine the individual contribution of MPR4 and Pgp to
camptothecin analog resistance, we used RNAi to reduce MRP4 or Pgp expression in
NB1691 and evaluate the effect on drug resistance. Knocking down MRP4 expression
resulted in reduced MRP4 function, i.e., increased intracellular accumulation of the
MRP4 substrate PMEA and topotecan. Reduced MRP4 expression and function also
resulted in increased sensitivity to both topotecan and SN-38. Moreover, exogenous
MRP4 overexpression conferred topotecan and SN-38 resistance in a neuroblastoma cell
line relatively sensitive to topotecan and SN-38.
As observed for MRP4, shRNA to Pgp reduced Pgp expression and function. In
NB1691 clones with reduced Pgp expression, intracellular accumulation of mitoxantrone,
a probe for Pgp function was increased. Topotecan intracellular accumulation was also
increased, resulting in increased sensitivity. However, reduced Pgp functional expression
did not result in an increase in SN-38 sensitivity. We reasoned that this may be due to a
compensatory increase in expression of an ABC transporter for which SN-38, but not
topotecan, is a substrate, such as MRP2. However, MRP2 expression did not differ
among the NB1691 MDR1 shRNA clones or controls. Therefore, we postulate that the
observed increase in SN-38 resistance in NB1691 MDR1 shRNA clone 3 may be due to
increased intracellular inactivation of the drug.
Although neuroblastoma xenograft models and patients exhibit responses to the
camptothecin analogs, there is a sensitivity continuum among both patients and
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xenografts. For example, NB1691 and NB143 were isolated from patients with stage D
neuroblastoma (70). NB1643 was established from a diagnostic tumor sample. In
contrast, the patient from whom NB1691 was derived had received prior therapy
including cytarabine, daunomycin, 6-thioguanine, etoposide, and 5-azacytidine. This
multi-agent chemotherapy may have acted as a selective pressure for a neuroblastoma
clonal population that expresses ABC transporters. However, it is also possible that the
ABC transporters expressed in NB1691 were present at the onset of disease and before
chemotherapeutic selection of resistant clones. Without a paired tumor specimen isolated
prior to therapy, it is not possible to determine whether NB1691 represents intrinsic or
acquired resistance. Regardless, we have demonstrated that NB1691 is a model of ABC
transporter mediated resistance to camptothecin analogs.
The findings that MRP4 and Pgp mediate resistance to the camptothecin analogs
in neuroblastoma have several potential applications. A gene therapy approach using
RNAi to knock down the expression of ABC transporters in the tumor may increase the
sensitivity of neuroblastoma to topotecan or irinotecan. Reducing the expression of ABC
transporters at the level of the tumor may also increase the sensitivity to other drugs
traditionally used in neuroblastoma, such as doxorubicin, vincristine, etoposide, and
cyclophosphamide. In addition to inhibiting ABC transporters by reducing protein
expression, drugs designed to inhibit ABC transporters such as valspodar or biricodar
may theoretically help to increase tumor levels of cytotoxic drugs. However, MDR
modulators have not significantly improved outcome in clinical trials (169,170,171).
In contrast to the MDR modulators biricodar or valspodar, other drugs that were
not initially designed as modulators of MDR have been shown to modulate MDR as a
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“side effect.” For example, the EGFR tyrosine kinase inhibitor gefitinib also inhibits
BCRP and Pgp (130,136). Combining gefitinib (or other similar compounds such as
erlotinib) with topotecan or irinotecan can take advantage of the cytostatic effect of
gefitinib in addition to its ability to increase tumor levels of cytotoxic compounds.
However, gefitinib inhibits ABC transporters expressed in normal tissues (e.g., kidney)
important in the pharmacokinetics of topotecan and irinotecan. Therefore, the interaction
between camptothecin analogs and EGFR tyrosine kinase inhibitors can be three-fold:
increasing camptothecin analog systemic exposure, inhibiting camptothecin analog efflux
from malignant cells, and pharmacologic interaction between EGFR inhibition and
topoisomerase I interaction.
Finally, the results of the current study may be useful in future trials of
individualizing therapy for patients with neuroblastoma. Determining the ABC
transporter expression profile on a diagnostic tumor sample can be used to select drugs
that are not substrates for the transporters expressed in an individual patient’s tumor.
However, the possibility remains that no drugs currently available will be predicted to be
effective in some children, especially with high-risk disease. Therefore, further
development of drugs that evade the ABC transporters and other resistance mechanisms
in children with neuroblastoma is required to improve the survival rate.
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Chapter 3.

Effect of MRP4 shRNA on NB1691 xenograft
response to topotecan

3.1

Introduction
Murine xenograft models are a useful preclinical tool for assessing response of

human tumors to chemotherapeutic agents. Anti-tumor response can be measured in
xenograft-bearing mice treated with various drugs or drug combinations. Furthermore,
various dosages and schedules of drug administration can be compared in murine
xenograft models.
A panel of six neuroblastoma xenograft models demonstrated a range of
responses to topotecan (155). A complete response to 3 intravenous topotecan courses
administered daily for 5 days for two weeks ([(dx5)2]3) was achieved in 4 of the 6
xenograft models at a dosage of 0.61 mg/kg. In contrast to the xenografts that responded
to topotecan, the relatively resistant neuroblastoma xenograft model NB1691 required a
topotecan dosage as high as 2 mg/kg to achieve a complete response. But a partial
response to this [(dx5)2]3 topotecan schedule was observed in NB1691 at a dosage of 1
mg/kg.
Efflux of topotecan by ABC transport proteins has been implicated in resistance
to topotecan. In a screen of ABC transport protein expression of neuroblastoma cell lines
cultured in vitro, we demonstrated that the relatively resistant NB1691 expressed both
MRP4 and Pgp (172), and topotecan is a substrate for both MRP4 and Pgp (114).
However, the relatively sensitive NB1643 did not express MRP4 or P-glycoprotein.
Therefore, we hypothesized that knocking down MRP4 or P-glycoprotein expression in
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NB1691 would increase the sensitivity of NB1691 to camptothecin analogs and yield a
response profile similar to NB1643 both in vitro and in vivo. As described in Chapter 2,
the in vitro studies of topotecan sensitivity in NB1691 in which shRNA was used to
reduce MRP4 expression demonstrated an increase in topotecan sensitivity.
The objective of this study was to evaluate the contribution of MRP4 expression
in neuroblastoma to tumor response to topotecan in vivo. Therefore, we established the
NB1691 MRP4 shRNA clones as xenografts in SCID mice. We measured the xenograft
response to topotecan [(dx5)2]3 at dosages previously shown to elicit partial and
complete responses in the NB1691 xenograft model.

3.2

3.2.1

Materials and methods

Knockdown via stable shRNA
MRP4 expression in NB1691 was knocked down in vitro using shRNA as

described in Chapter 2. Single cell clones were selected by FACS, expanded, and
characterized by Western blot and in vitro cytotoxicity assays. Cells (1x108) were
harvested and transplanted into the flanks of CB17/Icr female scid -/- mice.

3.2.2

Growth inhibition studies
Mice bearing s.c. tumors received topotecan when tumors were ~0.20 to 1 cm in

diameter (173). Tumor diameters were measured weekly using Vernier calipers.
Assuming tumors to be spherical, tumor volumes were calculated according to the
formula [(π/6) x d3] where d is the mean diameter. Tumor bearing mice were randomized
into groups of ten prior to therapy. One group was treated with vehicle control, and a
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second group was treated with topotecan. All mice were housed under barrier conditions.
All experiments were conducted using protocols and conditions approved by the St. Jude
Children’s Research Hospital Institutional Animal Care and Use Committee.

3.2.3

Drugs and formulation
Topotecan (GlaxoSmithKline, King of Prussia, PA) was formulated in 0.9%

saline and administered i.v. (0.05 mL/10g body weight) at a dose of 1 or 2 mg/kg as a
short injection (<1 minute) into the lateral tail vein. Mice received topotecan [(dx5)2]3.

3.2.4

Real-time RT-PCR
RNA was extracted from xenograft tissue with Tri-Reagent (Molecular Research

Center, Cincinnati, OH), and cDNA was synthesized using a mixture of oligo-dT and
random hexamer primers with the QuantiTect Reverse Transcription Kit (Qiagen,
Valencia, CA). Real-time PCR analysis was conducted using gene specific primers as
described in Chapter 2. Thermal cycling conditions were as follows: 15 min at 95°C
followed by 40 cycles of 95°C for 30 s, 60°C for 30 s, 72°C for 30 s, and finally a
denaturation stage. The mRNA expression level was determined by the comparative Ct
method. Student’s t-test (two-tailed) with Bonferroni correction was used to determine
differences in mRNA expression between NB1691 and MRP4 shRNA clones.

3.2.5

Immunohistochemistry
Neuroblastoma xenograft tissues were fixed in formalin and embedded in

paraffin. Sections (4 μm) were placed on positively charged slides. Slides were heated
(60°C) for 30 minutes and cleared of paraffin in CitriSolv (Fisher Scientific, Hampton,
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NH) and alcohol gradient solution panel prior to high temperature antigen recovery in
citrate buffer pH 6.0. Slides were blocked with 3% hydrogen peroxide in methanol and
avidin/ biotin blocking reagent (Vector Labs, Burlingame CA) prior to incubation with
the primary antibody. Irrelevant isotype fractions were used as negative controls.
Biotinylated secondary antibodies were used (Vector Labs), and the tertiary reagent was
streptavidin-horseradish peroxidase (Dako, Carpinteria, CA). Color development was
achieved with diaminobenzidine (DAB, Dako), and the slides were counterstained with
hematoxylin (Dako).

3.3

Results
As described in Chapter 2, the retroviral-vector mediated MRP4 shRNA reduced

MRP4 mRNA and protein expression in NB1691 clones 4.2 7 and 9 in vitro. When these
clones were transplanted into SCID mice as xenografts, all 4 cell lines (NB1691 parental,
GFP1 vector control, and clones 4.2 7 and 9) grew and developed palpable tumors.
However, on the second passage in vivo, clone 4.2 7 did not develop palpable tumors.
To determine the effect of reducing MRP4 expression in NB1691 on xenograft
response to topotecan, mice were treated at a topotecan dosage and schedule that had
previously elicited a partial response in NB1691 (1 mg/kg [(dx5)2]3). We hypothesized
that reduced MRP4 expression would be associated with a more pronounced antitumor
response in comparison to the parental cell line. Unexpectedly, none of the tumors
responded to topotecan 1 mg/kg (Figure 3.1). Therefore, we treated the xenografts on the
same schedule at a higher topotecan dosage (2 mg/kg). Again, unexpectedly none of the
xenografts responded to the higher topotecan dosage (Figure 3.2). NB1691GFP 4.2 7 was
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Figure 3.1
[(dx5)2]3.

NB1691 MRP4 shRNA xenograft response to i.v. topotecan 1 mg/kg

Tumor volume was measured weekly until tumor volume quadrupled. Mice were treated
with vehicle control (A-D) or topotecan daily for 5 days for 2 weeks every 21 days for up
to 3 courses (E-H). NB1691 (A, E); NB1691 GFP1 (B, F); NB1691 GFP 4.2 7 (C, G);
NB1691 GFP 4.2 9 (D, H). Each curve represents the growth of an individual tumor.
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Figure 3.2
[(dx5)2]3.

NB1691 MRP4 shRNA xenograft response to i.v. topotecan 2 mg/kg

Tumor volume was measured weekly until tumor volume quadrupled. Mice were treated
with vehicle control (A-C) or topotecan daily for 5 days for 2 weeks every 21 days for up
to 3 courses (D-F). NB1691 (A, D); NB1691 GFP1 (B, E); NB1691 GFP 4.2 9 (C, F).
Each curve represents the growth of an individual tumor.
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not included at the 2 mg/kg dosage because the xenografts did not grow after the second
passage in vivo.
To determine if ineffective MRP4 knockdown was related to failure to respond in
the NB1691 xenograft clones, we evaluated the MRP4 mRNA and protein expression in
the xenografts. In clone 4.2 7, real-time RT-PCR analysis demonstrated that MRP4
mRNA expression was approximately half the mRNA level in the parental xenograft
(Figure 3.3). Whereas, in vitro, the MRP4 mRNA expression level in clone 4.2 7 was
only 10% of the parental cell line (Figure 2.5). However, in clone 4.2 9 MRP4 mRNA
expression was not significantly reduced compared to NB1691 (Figure 3.3), indicating
that the MRP4 shRNA did not persist in this clone. Microscopic evaluation of xenograft
sections revealed green fluorescence, indicating that the GFP cassette had not been
silenced. Immunohistochemical staining of MRP4 in the NB1691 xenografts
demonstrated heterogeneous MRP4 expression in all four xenografts (Figure 3.4).
Therefore, effective MRP4 knockdown via shRNA did not persist in this in vivo
xenograft model.
Upregulation of other ABC transporters for which topotecan is a substrate may be
responsible for the lack of response in the MRP4 shRNA xenografts. Therefore we also
evaluated MDR1 and BCRP mRNA expression. MDR1 mRNA expression was only
significantly elevated in the GFP1 vector only xenograft (Figure 3.5). However, the
observed level of MDR1 expression in all four xenograft models may be sufficient to
confer in vivo resistance to topotecan. Real-time RT-PCR analysis demonstrated that
BCRP mRNA was expressed at low levels (Ct of approximately 30) in all four xenograft
models, and no significant difference was observed in expression level among them (data
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MRP4 mRNA expression in NB1691 MRP4 shRNA xenografts.

MRP4 mRNA expression is significantly reduced in NB1691 4.2 7 but not 4.2 9.*P<0.01
(t-test with Bonferroni correction).
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Figure 3.4

MRP4 is expressed in NB1691 MRP4 shRNA xenografts.

Immunohistochemical analysis of NB1691 MRP4 shRNA xenografts showing
heterogeneous membrane staining of MRP4 (brown stain). NB1691 (A); NB1691 GFP1
(B); NB1691 4.2 7 (C); NB1691 4.2 9(D). MRP4 shRNA did not effectively reduce the
MRP4 expression in NB1691 xenografts.
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MDR1 mRNA expression in NB1691 MRP4 shRNA xenografts.

MDR1 mRNA expression is significantly increased in NB1691 GFP1. *P<0.01 (t-test
with Bonferroni correction).
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not shown). BCRP was not expressed in the four xenograft models as determined by
immunohistochemical analysis. Therefore, in vivo expression of BCRP does not account
for the failure of these xenografts to respond to topotecan.

3.4

Discussion
In order to determine the contribution of MRP4 expression in vivo to response to

topotecan, we established the NB1691 clones transduced with MRP4 shRNA as
xenografts. SCID mice were treated with a protracted topotecan schedule that had
previously elicited a partial response in CBA/CaJ mice bearing NB1691 xenografts
(61).Unexpectedly, none of the 4 xenograft models responded to 1 or 2 mg/kg topotecan
[(dx5)2]3. To determine if MRP4 silencing via shRNA persisted in xenografts, we
analyzed MRP4 expression by real-time RT-PCR and immunohistochemistry. MRP4
mRNA expression was higher in vivo than in vitro. In addition, results of
immunohistochemical analysis demonstrated that MRP4 was heterogeneously expressed
in all four xenografts. Therefore, effective MRP4 shRNA did not persist in vivo.
However, expression of MRP4 in these four xenograft models and failure to respond to
topotecan are consistent with the hypothesis that MRP4 expression confers resistance to
topotecan.
The lack of response to topotecan of the parental NB1691 xenograft may be
attributable to variations in tumor growth or response in different strains of mice. The
partial response of NB1691 to 1 mg/kg topotecan was observed in CBA/CaJ mice (61).
The current study was conducted in SCID mice. Thompson and colleagues demonstrated
that NB1691 xenografts in SCID mice were less sensitive to topotecan than in the
CBA/CaJ host (174).
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Topotecan pharmacokinetics are similar in SCID and CBA/CaJ mice (Dr. Clinton
Stewart, unpublished data), so the difference between strains is not attributable to
variations in systemic exposure. SCID mice bearing NB1691 xenografts did not respond
to oral topotecan 2 mg/kg (Chris Morton, personal communication May 30, 2006). In
SCID mice the topotecan systemic exposure after an oral dose of 2 mg/kg is 55 ng/mL*hr
(136), approximately equivalent to that achieved by 0.36 mg/kg i.v. topotecan. In
CBA/CaJ mice bearing NB1691 xenografts, a partial response was achieved in mice
treated with 0.36mg/kg i.v. topotecan, indicating that variations in mouse strain may
impact the response of NB1691 xenografts to topotecan.
The NB1691 cell line used to establish xenografts had been maintained in tissue
culture. Cell lines maintained in tissue culture are subject to alterations (175) that may
influence sensitivity to cytotoxic drugs including topotecan. For example, promoter
methylation and silencing of apoptosis-related genes can occur during passage in tissue
culture (176). Genetic instability including chromosomal gains, losses, or translocation
and gene amplification or deletion can also accumulate during tissue culture passage
(176). Enhanced recombinatorial repair of topotecan-induced DNA strand breaks has
been implicated in camptothecin analog resistance and may occur during passage over
time in culture (177). Inhibition of cell death signaled by topotecan-induced DNA lesions
may also result in topotecan resistance. Alternatively, enhanced activity of the DNA
repair enzyme MGMT can result in topotecan resistance (178). Any of these alterations
may account for the failure to respond to topotecan in vivo.
Despite the decreased sensitivity of NB1691 xenografts in SCID mice, we
predicted that xenografts derived from the MRP4 shRNA clones would be more sensitive
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to topotecan than the parental cell line. However, we did not observe differences in vivo
response based on MRP4 expression.
Failure of the MRP4 shRNA may be attributed to retroviral vector silencing. Gene
expression has been silenced in retroviral vectors containing the MLV LTR. This
silencing is mediated by the binding of ELP, an embryonal LTR-binding protein that
suppresses transcription of the MLV LTR. However, expression of the MRP4 shRNA
cassette in the MSCV retroviral vector that we used was directed by the PCMV LTR in
which the ELP binding site has been deleted, decreasing the potential for retroviral vector
silencing (160,179). Furthermore, GFP expression in all of the transduced xenografts was
visualized with fluorescence microscopy, suggesting that the retroviral vector was not
silenced in vivo.
The disparity in the effect of MRP4 expression on topotecan sensitivity observed
in vitro and in vivo may also be due in part to differences in the in vitro and in vivo
environments. For example, Mattern et al demonstrated that resistance conferred by ABC
transporters in vitro was not be recapitulated in vivo for the camptothecin analogs (73).
Pgp expression in vitro conferred 15-35 fold resistance to topotecan. In contrast, Pgp
expression in vivo did not significantly alter topotecan sensitivity.
The hypoxic tumor microenvironment may contribute to the disparity between in
vitro and in vivo sensitivity to topotecan observed in our studies. MRP4 expression may
have been induced in the hypoxic tumor microenvironment, overwhelming any RNAimediated knockdown in MRP4 expression. Recent in vitro studies have demonstrated
increased MRP4 mRNA expression in NB1691 after 24 hours of hypoxia (Dr. Stacy
Throm, personal communication March 14, 2007). BCRP expression is also induced
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under hypoxia via the HIF-1 pathway in placental choriocarcinoma, osteosarcoma, and
acute myelogenous leukemia cell lines (180). The hypoxic tumor microenvironment
stands in contrast to the oxygen replete in vitro environment that permits persistent
MRP4 knockdown and differential topotecan sensitivity based on MRP4 expression.
The results of these studies highlight the differences between in vitro and in vivo
environments. While we observed shRNA mediated MRP4 reduction in vitro that
correlated with increased sensitivity to the camptothecin analogs, the same patterns were
not recapitulated in the xenograft models.
Although the goal of these experiments was to determine the effect of MRP4
expression in vivo on the response of neuroblastoma to topotecan, the results do not
provide an answer to this research question. However, because all of the NB1691 clones
studied herein expressed MRP4 and failed to respond to topotecan, the results of these
studies are consistent with the hypothesis that MRP4 expression confers resistance to
topotecan and may be a factor in failure of some neuroblastomas to respond. Future
studies in which MRP4 can be effectively silenced in vivo will be required to address this
issue definitively.
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Chapter 4.

ABC transporter expression in neuroblastoma
biopsy specimens from children treated with
pharmacokinetically guided topotecan

4.1

Introduction
The camptothecin analog topotecan is active against neuroblastoma in preclinical

xenograft models. Based on the preclinical activity of topotecan in models of childhood
solid tumors, topotecan has been evaluated in phase I and II clinical trials in children. In a
phase II trial of topotecan in 30 children with high-risk neuroblastoma, a complete
response was observed in 1 child, and partial responses were observed in 17 children for
a response rate of 60% (15). Despite this favorable response to topotecan, a higher
response rate was predicted based upon the anti-tumor activity of topotecan in
neuroblastoma xenograft models. The 40% of children with high-risk neuroblastoma who
did not respond to topotecan represent a subset of the population resistant to topotecan.
We have also demonstrated in neuroblastoma cell lines in vitro that the ABC
transporters MRP4 and Pgp confer topotecan resistance. Thus, the objective of the current
study was to evaluate the potential relation between ABC transport protein expression
and clinical response to topotecan. Therefore, we evaluated the expression of ABC
transporters for which topotecan is a substrate (i.e., MRP4, Pgp, and BCRP) in tumor
specimens from children enrolled on the phase II trial of topotecan in high-risk
neuroblastoma. We used immunohistochemistry to determine the plasma membrane
expression of ABC transport proteins in neuroblastoma samples.
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4.2

4.2.1

Materials and methods

Patients
All patients evaluated in this retrospective study were enrolled on a phase II trial

of pharmacokinetically guided topotecan at St. Jude Children’s Research Hospital (15).
Patients enrolled on the phase II trial had previously untreated high-risk neuroblastoma
(i.e., INSS stage 3 or 4 disease in children older than 1 year or MYCN amplified stage 3
or 4 disease in children younger than 1 year). The St. Jude Institutional Review Board
approved this retrospective study.

4.2.2

Tumor specimens
We attempted to evaluate ABC transporter expression in bone marrow aspirates

obtained prior to therapy. However, the acid decalcification of these specimens prevented
effective antigen retrieval and immunohistochemical detection of the proteins of interest.
Therefore, we used formalin-fixed paraffin-embedded tumor specimens obtained during
resection of the primary tumor after two cycles of topotecan and standard induction
therapy including cyclophosphamide, doxorubicin, etoposide, cisplatin, ifosfamide, and
carboplatin.

4.2.3

Definitions of response to pharmacokinetically guided topotecan
Response to pharmacokinetically guided topotecan was evaluated after two cycles

and defined by extent of tumor regression. A complete response (CR) was more than
90% regression of the primary tumor and complete resolution of metastatic disease. A
partial response (PR) was more than 50% regression of all disease. An objective response
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(OR) was 25-50% tumor regression. Stable disease (SD) was less than 25% tumor
regression without tumor progression. Patients with a CR or PR were classified as
responders, and those with OR or SD were classified as non-responders. Standard
radiographic methods (e.g., CT scans, MRI scans) were used to evaluate response.

4.2.4

Immunohistochemistry
Sections (4 μm) of formalin-fixed paraffin-embedded neuroblastoma were placed

on positively charged slides. Slides were heated (60°C) for 30 minutes and cleared of
paraffin in CitriSolv (Fisher Scientific, Hampton, NH) and alcohol gradient solution
panel prior to high temperature antigen recovery in citrate buffer pH 6.0. Slides were
blocked with 3% hydrogen peroxide in methanol and avidin/ biotin blocking reagent
(Vector Labs, Burlingame CA) prior to incubation with the primary antibody. MRP4 was
probed with the rat anti-human monoclonal antibody M4I-10 (Axxora). BCRP was
probed with the rat anti-human and mouse monoclonal antibody BXP-53 (Axxora). Pgp
was probed with the mouse anti-human monoclonal antibody JSB-1 (Signet Labs).
Irrelevant isotype fractions were used as negative controls. Biotinylated secondary
antibodies were used (Vector Labs), and the tertiary reagent was streptavidin-horseradish
peroxidase (Dako, Carpinteria, CA). Color development was achieved with DAB (Dako),
and the slides were counterstained with hematoxylin (Dako). Human kidney sections
were used as positive controls for MRP4, Pgp, and BCRP staining.
Stained slides were visualized under a light microscope at 40x magnification.
Only tumors with membrane staining of tumor cells were considered positive for
expression of the individual transporters. Staining of endothelial cells within the tumor
was not scored as positive.
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4.2.5

Statistical considerations
The Fisher exact test was used to determine if the children for whom tumor

samples were available were representative of the study population in terms of response
to topotecan. The Fisher exact test was also used to determine if ABC transporter
expression was a significant indicator of response to topotecan. All tests were two-tailed.

4.3

Results
Neuroblastoma sections were available from 14 out of 28 evaluable patients. The

positive and negative controls in human kidney are depicted in Figure 4.1. MRP4, Pgp,
and BCRP are expressed in the brush border of the proximal convoluted tubule. No
staining was noted in the isotype negative controls.
Out of the 14 available neuroblastoma sections, MRP4 was expressed in 2, Pgp
was expressed in 4, and BCRP was expressed in 9 (Table 4.1). Neuroblastomas from four
of eight responders expressed at least one of the ABC transporters evaluated. Tumors
from four of the six non-responders expressed at least one of the ABC transporters
evaluated. The neuroblastoma section from patient nine was representative of all
specimens in which MRP4 was not expressed (Figure 4.2A). MRP4 was expressed in the
membrane of neuroblastoma cells from patient number seven (Figure 4.2B). Pgp was not
expressed in the neuroblastoma specimen from patient 13 (Figure 4.2C). Pgp was
localized to the plasma membrane of neuroblastoma cells from patient number ten
(Figure 4.2D), but was heterogeneous and localized to only a few regions of the tumor
specimen. This pattern of sporadic Pgp staining was representative of all Pgp positive
specimens. BCRP was not expressed in the neuroblastoma cells from patient three
(Figure 4.2E). The tumor from patient two expressed BCRP (Figure 4.2F).
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Figure 4.1

ABC transporter expression in human kidney controls.

Left column: irrelevant IgG negative control. Right column: positive control. Rat IgG
(A); M4I-10 (B); Mouse IgG (C); JSB-1 (D); Rat IgG (E); BXP-53 (F). Brown staining in
panels B, D, and F indicate localization of MRP4, Pgp, and BCRP to brush border of the
proximal tubules. All images are shown at 40x magnification.
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Table 4.1
ABC transporter expression in neuroblastoma specimens and
response to pharmacokinetically guided topotecan.
Patient Number

Response

1
2
3
4
5
6
7
8
9
10
11
12
13
14

PR
PR
PR
PR
PR
PR
PR
PR
OR
OR
SD
SD
SD
SD

MRP4
expression
+
+
-

Pgp
expression
+
+
+
+

BCRP
expression
+
+
+
+
+
+
+
+
+

Abbreviations: MRP4- multi-drug resistance associated protein 4; Pgp- P-glycoprotein;
BCRP- breast cancer resistance protein; PR-partial response; OR- objective response;
SD- stable disease
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Figure 4.2
ABC transporter expression in neuroblastoma tissue obtained during
primary tumor resection.
Patient 9: MRP4 negative (A); Patient 7: MRP4 positive (B); Patient 13: Pgp negative
(C); Patient 10: Pgp positive (D); Patient 3: BCRP negative (E); Patient 2: BCRP positive
(F). All images are shown at 40x magnification.
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Despite expression of MRP4, Pgp, or BCRP in neuroblastoma, these ABC
transporters were not statistically related to response to pharmacokinetically guided
topotecan (P> 0.05, Fisher Exact test). There was an essentially even distribution of ABC
transporter protein expression among responders and non-responders to topotecan.
However, this was a small sample size and may not be sufficiently powered to detect a
difference in ABC transporter expression between responders and non-responders.

4.4

Discussion
We used immunohistochemistry to detect the expression of MRP4, Pgp, and

BCRP in primary neuroblastoma sections and determined the relation to topotecan
response. When compared to methods such as RT-PCR to detect mRNA expression
(10,11,12,110) this immunohistochemical approach prevented contamination of ABC
transporter expression in normal cells (e.g., vascular endothelium) that may obscure
results. This immunohistochemical approach also permitted detection of ABC
transporters localized to the plasma membrane of neoplastic cells
Based on the possibility of chemotherapy related induction or selection of ABC
transporters, we initially attempted to determine the ABC transporter expression profile
in bone marrow aspirates obtained prior to therapy. However, acid decalcification of the
bone marrow aspirates prevented antigen retrieval and detection of ABC transporter
expression. Due to the availability of formalin-fixed, paraffin-embedded primary tumor
tissue we decided to evaluate the ABC transporter expression in these samples. However,
these tumors were resected after two topotecan cycles and standard multi-agent induction
therapy. In these available samples, expression of MRP4, Pgp, or BCRP was not related
to failure to respond to topotecan.
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Previous studies have demonstrated that high levels of Pgp and MRP4 mRNA
expression are predictive of poor outcome in neuroblastoma. Several factors may explain
why a relation between MRP4/Pgp/BCRP expression and the clinical response to
pharmacokinetically guided topotecan was not detected in the current study. The ABC
transporter expression profile in the primary tumor may have changed as a result of
induction therapy. Whereas cyclophosphamide, doxorubicin, and etoposide may be
subject to ABC transporter mediated resistance, cisplatin, ifosfamide, and carboplatin
may have eliminated the MRP4/Pgp/BCRP expressing clones responsible for failure to
respond to topotecan. Although this phenomenon is the rationale for multi-agent
chemotherapy, exposure of the neuroblastoma specimens to these drugs may have
confounded our results.
Norris and colleagues demonstrated MRP4 mRNA expression in 100% of 52
neuroblastomas from untreated patients (110). In this population of 52 patients, high
MRP4 mRNA expression was a significant indicator of poor survival. The previous
studies demonstrating a relation between ABC transporter expression and outcome
evaluated mRNA, not protein expression (11,12,10). Although the real-time RT-PCR
method permits simple and rapid quantitation of mRNA expression in tumor homogenate,
this method does not necessarily isolate tumor tissue from normal tissue such as blood
vessels. This is particularly problematic for the ABC transporters, which are expressed in
vascular endothelial cells. Furthermore, the tissue must be preserved in order to isolate
high quality RNA, and a technique such as laser capture microdissection should be used
to isolate neuroblastoma cells from endothelia (181). Immunohistochemistry permits
detection of ABC transporter subcellular localization. Cytosolic localization of a
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transporter would not likely result in resistance because the transporter is not oriented to
efflux substrates from the cell.
Whether response to topotecan predicts long-term outcome such as overall
survival or event-free-survival remains to be determined. Evaluating whether the ABC
transporter protein expression profile in the primary or metastatic tumor at any point
(before, during, or after therapy) predicts outcome may help to improve the response of
neuroblastoma to the camptothecin analogs. To accomplish this in a clinical study of
children with neuroblastoma, the question about correlation between ABC transporter
mRNA and protein expression must first be addressed. ABC transporter expression in the
same tumor sample should be evaluated using both real-time RT-PCR and
immunohistochemistry. Next, ABC transporter expression should be evaluated before
and after therapy to determine the influence of chemotherapy on ABC transporter
expression. Finally, a clinical study should be sufficiently powered to determine the
relationship between ABC transporter expression and clinical outcome in children with
neuroblastoma.
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Chapter 5.

Summary and future directions

Neuroblastoma is the most common extracranial solid tumor in children. Patients
who present with localized disease have excellent predicted survival. However, most
children diagnosed with neuroblastoma are at high-risk for a poor outcome because they
present with metastatic disease and/ or other unfavorable biological features including
MYCN amplification. Therapy for children who are diagnosed with high-risk disease can
include multi-agent chemotherapy, myeloablation with bone marrow transplant/ stem cell
rescue, surgery, and radiation. Despite this intense therapy, five-year survival in children
with high-risk neuroblastoma is much less favorable than for those with low- or
intermediate-risk disease (30 to 40% compared to 80 to 95%).
One of the approaches recently evaluated for improving the outcome in children
with high-risk neuroblastoma is pharmacokinetically guided topotecan dosing (49,15).
This approach was based on significant anti-tumor activity of topotecan systemic
exposures of 100 ng/mL*hr in neuroblastoma xenograft models. Because topotecan
clearance in children varies at least 10-fold and in animal models topotecan anti-tumor
activity depends on systemic exposure, topotecan dosage was individualized to achieve a
targeted systemic exposure of 80 to 120 ng/mL*hr in children with newly diagnosed
high-risk neuroblastoma. Pharmacokinetically guided topotecan dosing was feasible in
this population, and the response to this single agent was considered excellent. However,
a significant proportion of children (40%) did not respond to topotecan and represent a
subset of the disease that is resistant to topotecan.
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ABC transporter mediated efflux of topotecan from neoplastic cells has been
implicated in topotecan resistance. The ABC transporters for which topotecan is a
substrate include Pgp, MRP1, MRP4, and BCRP. ABC transporters also confer resistance
to other cytotoxic drugs traditionally used in high-risk neuroblastoma therapy (i.e.,
doxorubicin, etoposide, and vincristine). Furthermore, MRP1, Pgp, and MRP4 are
expressed in neuroblastoma, and high levels of mRNA expression of these transporters is
predictive of poor overall survival and event-free survival (10,11,12,110). However, the
relation between expression of ABC transport proteins in neuroblastoma cells and antitumor response to ABC transporter substrates has not been evaluated.
The major objective of these studies was to evaluate the relation between
expression of ABC transport proteins in neuroblastoma and response to the camptothecin
analogs topotecan and SN-38. The first specific aim was to determine the contribution of
ABC transporters to topotecan and irinotecan/SN-38 sensitivity in neuroblastoma cell
lines. After identifying ABC transporters that confer resistance to camptothecin analogs
in vitro, we evaluated the contribution of ABC transporter expression in neuroblastoma
xenografts to topotecan response in vivo. Finally, we assessed the relation between
expression of ABC transporters in neuroblastoma biopsy specimens and the anti-tumor
response to pharmacokinetically guided topotecan.
First, by western blot analysis we screened a panel of neuroblastoma cell lines
with a range of sensitivity to topotecan for expression of ABC transporters. NB1691, the
most topotecan resistant cell line evaluated, expressed both MRP4 and Pgp. In contrast,
NB1643, the most topotecan sensitive cell line evaluated, expressed neither MRP4 nor
Pgp. Based upon these results, we determined the effect of reducing MRP4 and Pgp
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expression via shRNA in NB1691 on topotecan and SN-38 sensitivity. As expected,
topotecan sensitivity increased in NB1691 clones with reduced MRP4 and Pgp protein
expression. We also demonstrated that topotecan sensitivity was reduced upon
overexpression of MRP4 in NB1643.
To determine if the increased in vitro topotecan sensitivity in NB1691 MRP4
shRNA clones translated into increased sensitivity in vivo, we established these NB1691
clones as xenografts in SCID mice. Mice bearing neuroblastoma xenografts were treated
with topotecan at dosages that had been shown to elicit at least 50% tumor volume
regression in NB1691 xenografts (155). Unexpectedly, no tumor regression was observed
in any of the xenografts evaluated. Furthermore, no difference was noted in response to
topotecan between the parental NB1691 and the MRP4 shRNA clones. Most likely this
occurred because MRP4 knock down did not persist in vivo.
Because the rationale for this study of ABC transporters in camptothecin analog
resistance was based upon the failure to respond to topotecan in 40% of children with
high-risk neuroblastoma in a phase II trial, we also retrospectively evaluated the ABC
transporter expression profile in neuroblastoma specimens from that phase II trial. Based
on the in vitro data demonstrating increased sensitivity to topotecan in neuroblastoma
clones with reduced MRP4 and Pgp expression, we reasoned that MRP4 and/ or Pgp
would be expressed in neuroblastoma tissue from children who did not respond to
topotecan. However, results of immunohistochemical detection of ABC transport protein
in the membrane of neuroblastoma cells demonstrated that expression of MRP4, Pgp, or
BCRP was not related to response to topotecan. Because this analysis could not be
conducted on tissue prior to therapy, the results may be confounded by the effects of
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multi-agent chemotherapy. Including tumor samples obtained prior to chemotherapy and
preserved to ensure optimal antigen recovery in future clinical studies of neuroblastoma
may permit a broader assessment of the impact of ABC transporter expression on antitumor activity of drugs.
The findings from the in vitro and xenograft studies conflict with the results of
evaluation of clinical samples from children with neuroblastoma. The in vitro studies
demonstrated that MRP4 and Pgp confer resistance to topotecan. The xenograft studies
pointed towards a potential association between MRP4 expression and failure to respond
to topotecan. But the lack of association between ABC transporter expression in the
clinical samples and response to topotecan may be confounded by the timing of sample
acquisition after two topotecan courses and induction therapy. More than highlighting the
limitations of experimental models of neuroblastoma, the implications of our results also
highlight the importance of determining ABC transporter expression prior to potential
clonal selection by multi-agent chemotherapy in children with neuroblastoma. However,
further preclinical xenograft studies and clinical studies will have to be conducted to
determine the contribution of ABC transporter protein expression to response to
individual drugs and overall outcome in neuroblastoma.
The ABC transporter superfamily is only one class of proteins that influences
anti-tumor response to drugs used in neuroblastoma therapy. Novel determinants of
response could also be identified using mRNA gene expression arrays or single
nucleotide polymorphism (SNP) chip arrays on laser capture microdissected tumor tissue.
If tumor samples can be obtained at discrete time points during therapy including at
diagnosis, after induction, consolidation, and bone marrow transplant, therapy could
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potentially be individualized and optimized based upon changes in gene expression
signature.
Further preclinical studies could also be conducted to assess the effect of ABC
transporter expression on anti-tumor response in neuroblastoma. For example, a mouse
model of neuroblastoma could be developed to address the contribution of ABC
transporters to tumor pathology and response to drugs. To accomplish this, the MRP4
deficient mouse (114), for example, could be crossed with the transgenic mouse model
overexpressing MYCN in neuroectodermal cells(182). Other ABC transporter knock out
models including Bcrp and Mdr1a/1b models could also be crossed with the MYCN
transgenic mouse. If the progeny of these crosses were viable, neuroblastoma
development could be compared to the parental MYCN transgenic mouse to assess the
role of ABC transporters in tumor formation. If tumors form in the progeny, they could
be treated with various drugs including topotecan and irinotecan to determine the effect
of ABC transporters on tumor response. But there is a caveat that the absence of an ABC
transporter in normal tissues such as the kidneys will alter the pharmacokinetics of the
drug. So an appropriate dosage that yields equivalent systemic exposures in the MYCN
transgenic mouse and the MRP4 knockout/ MYCN transgenic progeny must be
determined empirically.
As ABC transporter expression is upregulated by hypoxia in osteosarcoma, acute
myelogenous leukemia, and choricarcinoma cell lines(180), the role of hypoxia in
resistance to topotecan and irinotecan should be assessed. In future xenograft studies,
administration of RNAi in vivo (183) may permit more precise control over reduction of
ABC transporter expression in the hypoxic tumor microenvironment.
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Pharmacokinetically guided topotecan in combination with other agents (e.g.,
etoposide (184), cyclophosphamide (3), vincristine (185), and gefitinib (130,136)) may
be an effective approach to improve long-term survival in high-risk neuroblastoma and
other pediatric cancers. In evaluating these combinations, it will be important to use
appropriate drug sequences, schedules, dosages, and systemic exposures in order to
minimize host toxicity and maximize anti-tumor response. Additional analysis of the role
of ABC transport protein expression in clinical response to these combinations may
further improve the utility of the camptothecin analogs in neuroblastoma.
In conclusion, our studies show that MRP4 and Pgp confer resistance to topotecan
and SN38 in neuroblastoma. We developed an RNAi approach to silencing the
expression of these ABC transporters in neuroblastoma to determine the contribution to
camptothecin analog resistance. Future studies in children with neuroblastoma will
further delineate the clinical relevance of our findings. The application of these data in
the care of children with neuroblastoma may ultimately improve clinical outcome.
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